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Summary 
The evolutionary success can be simply described as persistence of an organism in its 
environment. This thesis is a story of bacterial adaptation and persistence in chronic 
infection. 
The ability of bacterial pathogens to colonize and establish lifetime persistence in 
the host is a fundamental problem for infectious disease control. Very often this 
persistence is a procedure of adaptation of pathogens driven by selective forces 
imposed by the host environment. Despite many years of intensive research, we have 
very limited knowledge about the basis of this process. Experimental evolution using 
microorganisms has allowed us to unravel dynamics and genetic details of adaptation 
when bacteria were propagated to replicate for many generations in a novel 
environment. However, these investigations were mainly performed with isolated 
pure cultures evolving under defined conditions. It is extremely interesting to 
uncover the mechanisms of bacterial adaptation in ‘real-world’ disease cases, and 
assess the compatibility of these with current evolutionary theories drawn from 
experimental evolution studies. 
Our model system is Pseudomonas aeruginosa chronic infection in cystic fibrosis (CF) 
patients. CF is a genetic disorder that mainly leads to deficient mucociliary clearance 
and microbial colonization in the airway mucus. The ubiquitous bacterium P. 
aeruginosa is the most prevalent pathogen in CF patients and to a large extent 
responsible for decreased lung function. A unique collection of P. aeruginosa isolates 
from CF patients in the Copenhagen CF centre initiated since 1973 allowed us to 
follow the adaptation process of this bacterium in CF airways for over 35 years.  
Typically, CF patients acquire P. aeruginosa from the environment and the bacteria 
persist in the airway through genetic adaptation. Compared to environmental isolates 
or standard lab strains, P. aeruginosa strains isolated from CF patients showed 
reduced growth rates as the infection progresses. Using fluorescent in situ 
hybridization (FISH) we could estimate the in vivo growth activity of P. aeruginosa in 
the CF airway by measuring the ribosome content. Surprisingly the majority of the 
cells are actively growing and the average in situ doubling time is between 100-150 
min. This ensured high turn-over rate of biomass and enormous possibilities for 
genetic changes. 
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One genotype that we have focused is the b clone that has been dominant and 
transmissible in many chronic patients. Since its first appearance in 1973 this clone 
has evolved in different patients for more than 150,000 generations. Since the human 
airway is a complex environment, intuitively one would imagine that adaptation 
would create diversity. However, adapted b strains isolated from different patients 
have remarkable similarity when we measured the transcriptome and catabolic 
functions. We also found that very few mutations in the evolution of b clone 
significantly enhanced the adaptation and allowed it to successfully sweep across 
many patients. Those important mutations occurred very early in the global 
regulators and have great impact on the overall pattern of expression levels and 
phenotypes. These findings resemble the evolution trajectory concluded from 
experimental microbial evolution studies. Besides, parallel evolution traits have also 
been observed, in which similar phenotypic changes occurred through independent 
genetic alterations. The overall result of the evolution of P. aeruginosa in CF airway for 
the b genotype is that it drifted away from the ancestor in terms of genetic content 
and various phenotypes, directing the consequence of creating specialists good at 
reproducing in the stressful environment in human CF lung. At the same time, the 
adapted strain seems to behave like a generalist capable of occupying all different 
niches in the lung, since we did not observe an increase of diversity during the 
evolution.  
  
9 | P a g e  
 
Dansk Resumé 
Patogene bakteriers evne til at kolonisere og etablere livsvarig infektion i væ rten er et 
grundlæ ggende problem for bekæ mpelsen af infektionssygdomme. Et eksempel på 
bakteriers vedholdenhed i væ rten ses ved kronisk infektion med bakterien 
Pseudomonas aeruginosa (P. aeruginosa) i cystisk fibrose (CF) patienter, som opnås 
gennem genetisk tilpasning til miljøet i CF patienters luftveje. Siden 1973 er P. 
aeruginosa isolater fra CF patienter tilknyttet Københavns CF center blevet gemt i en 
unik samling, hvilket har gjort os i stand til at følge bakteriens tilpasningsproces til 
CF luftvejene over en periode på mere end 35 år.  
CF patienterne bliver typisk inficeret med P. aeruginosa fra miljøet, hvorefter 
bakterierne forbliver i luftvejene vha. genetiske adaptationer. P. aeruginosa isolater fra 
CF patienter vokser langsommere end isolater fra miljøet eller standard laboratorie-
stammer og efterhånden som infektionen skrider frem bliver denne forskel endnu 
mere markant. Vi har anvendt fluorescent in situ hybridization til at bestemme 
mæ ngden af ribosomer i P. aeruginosa prøver fra CF patienter, hvorudfra vi kan 
estimere in vivo væ ksthastigheden for P. aeruginosa i CF luftvejene. Overraskende 
viste det sig, at størstedelen af cellerne er aktive og vokser med en gennemsnitlig in 
situ fordoblingstid på 100-150 min. Som følge heraf må der væ re en høj 
omsæ tningshastighed af biomasse i CF luftvejene og et enormt potentiale for 
genetiske æ ndringer.  
Vi har fokuseret på en genotype kaldet den b klon, som har væ ret dominerende 
og er blevet overført mellem mange kronisk inficerede patienter. Den b klon blev 
opdaget første gang i 1973 og har indtil nu udviklet sig i forskellige patienter i mere 
end 150.000 generationer. Som følge af det komplekse miljø, som de humane luftveje 
udgør, kunne man umiddelbart forvente at tilpasning til luftvejene ville resultere i 
diversitet. Imidlertid har vi observeret, at adapterede b stammer isoleret fra 
forskellige patienter udviser påfaldende ligheder i deres transkriptom og kataboliske 
kapacitet. Ydermere har vi for udviklingen af den b klon set, at fåtal af mutationer er 
ansvarlige for meget af adaptationen af den klon og at disse mutationer har gjort 
klonen i stand til at sprede sig til mange patienter. Mutationerne opstod tidligt i 
forløbet i gener kodende for globale regulatorer og har stor indvirkning på 
transkriptomet og stammernes fæ notyper. Disse resultater minder om de 
evolutionsforløb, som er blevet observeret under eksperimentelle evolutionsstudier 
med mikroorganismer. Derudover er der også blevet observeret parallel evolution af 
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karakteristika, hvor forskellige genetiske æ ndringer har medført ens fæ notypiske 
æ ndringer. Overordnet gæ lder der for udviklingen af P. aeruginosa i CF luftvejene for 
den b genotype, at udviklingen mod specialister, som er gode til at overleve i den 
humane CF lunges stressende miljø, har medført, at den b genotype er afveget fra 
stamfaderen i forhold til arvemasse og forskellige fæ notyper. 
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Chapter 1 Introduction 
1.1 Pseudomonas aeruginosa - an opportunistic pathogen 
1.1.1 P. aeruginosa – a generalist in different environments 
Pseudomonas aeruginosa is a motile rod-shaped Gram-negative bacterium (Figure 1) 
belonging to the genus Pseudomonas, which consists of several species of 
environmental bacteria.  It is ubiquitous in soil and water, and able to colonize plants, 
insects and mammals. It does not grow fermentatively but is capable to grow 
anaerobically using nitrate or arginine as respiratory electron acceptors. P. aeruginosa 
grows as high as 42°C but optimally at 37°C, which is a feature enabling it to become 
the only animal pathogen in Pseudomonas genus. In human beings, P. aeruginosa is an 
opportunistic pathogen infecting immunocompromised patients, such as those with 
chronic obstructive pulmonary disease, severe burns and in intensive care units. P. 
aeruginosa can either invade tissues and blood and cause acute infections like 
bacteraemia, or colonize mucosal surface and develop chronic infections like in cystic 
fibrosis (CF) patients. In a surveillance study of patients in the intensive care unit in 
Europe, P. aeruginosa was accountable for 30% of pneumonias, 19% of urinary track 
infections, and 10% bloodstream infections (Spencer, 1996). P. aeruginosa has been 
ranked in the top 3 pathogens in human beings due to its wide existence in the 
environment and extreme difficulties in medical treatment. Therefore, it is of great 
importance to understand its pathogenicity and mechanisms of counteracting 
antimicrobial therapies. 
The ability of P. aeruginosa to thrive in very diverse ecological niches and switch 
life styles quickly upon changing conditions is consistent with its relatively large 
genome size and the complex regulatory networks. The first P. aeruginosa genome was 
sequenced in 2000 using the strain PAO1, which is 6264,404 base pair and has 5570 
open reading frames (ORFs) (Stover et al., 2000). This genome size is comparable to 
the simple eukaryote Saccharomyces cerevisiae which has a genome encoding 6200 
proteins (Ball et al., 2000). Among the around 50% ORFs that have been assigned 
functional classes, PAO1 carries 517 genes encoding proteins with motifs of 
transcriptional regulators or two-component regulatory systems and 558 transporters 
14 | P a g e  
 
of small molecules, which corresponds to 9.3% and 10.0% of the genome respectively 
(Kulasekara & Lory, 2004). This large fraction of regulators and transporters further 
reflects its capability to respond to various stimuli and survive in different 
environments. To date, there are 7 P. aeruginosa genomes available in the National 
Center for Biotechnology Information (NCBI) genome database.   
 
Figure 1. Fluorescent in situ hybridization (FISH) staining of P. aeruginosa culture with 
probes targeting 16S RNA (This work). 
1.1.2 The mechanisms of antibiotic resistance by P. aeruginosa 
P. aeruginosa is one of the ‘superbugs’ that can be multi-resistant to various antibiotics. 
The molecular mechanisms of resistance include efflux pumps, mutation on targets of 
antibiotics, membrane modification, expression of enzymes that destruct the drugs, 
etc. The efflux pump systems are secondary transporters or ATP-Binding Cassette 
(ABC) transporters that export a variety of agents including antibiotics, biocides, dyes, 
organic solvents, detergents, etc.  P. aeruginosa has relatively high intrinsic antibiotic 
resistance due to efflux of the drugs (Li et al., 2004). Based on amino acid identity, 
bacterial efflux pumps are categorized into five superfamilies:  the ABC family, the 
resistance-nodulation-division (RND) family, the small multidrug resistance family, 
the major facilitator superfamily and the multidrug and toxic compound extrusion 
family (Lister et al., 2009).  
P. aeruginosa has efflux systems from all five superfamilies with largest number of 
predicted pumps belonging to the RND family (Stover et al., 2000). RND efflux pump 
systems are the most important family because they are associated with multi-
resistance of P. aeruginosa to a variety of clinically relevant antibiotics. The 
characteristics of all twelve RND efflux pumps in P. aeruginosa are listed in Table 1. 
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Two of them are divalent metal cation transporters (CzrCBA and products of PA2525-
PA2528). Efflux pump systems have different substrate spectrums with overlaps and 
they also differ in preferences of the same antibiotic class. For example, both MexAB-
OprM and MexCD-OprJ can export β-lactams but MexCD-OprJ has a more narrow 
substrate profile of only the fourth-generation cephalosporins like cefepime (Lister et 
al., 2009). 
RND pumps typically contain a cytoplasmic membrane transporter (RND), a 
periplasmic membrane fusion protein (MFP) and an outer membrane factor (OMF). 
Figure 2 illustrates the structure of a three-component RND efflux pump system, 
MexAB-OprM. The pump (MexB, RND) lies in the cytoplasmic membrane and the 
exit portal (OprM, OMF) is located in the outer membrane. They are linked via a 
lipoprotein (MexA, MFP). The efflux of drugs is coupled with the influx of proton.  
 
Figure 2. Structure of MexAB-OprM (Schweizer, 2003). The pump MexB (in the cytoplasmic 
membrane) is linked to the exit portal OprM (in the outer membrane) through lipoprotein 
MexA. The efflux of drugs is coupled with the influx of H+. 
Details of antibiotics resistance conferred by efflux pumps are described in 
following sections, however, one should know that efflux pumps are more than just 
resistance. They actually play other physiological roles that have great clinical 
relevance (Piddock, 2006). For example, in P. aeruginosa MexAB-OprM is the major 
player of intrinsic resistance (Poole et al., 1993) and this system has very broad 
substrate spectrum (Table 1), including cell-produced quorum sensing (QS) signal 
homoserine lactones (HSL) (see section 1.1.3). The expression of mexAB-oprM is 
growth phase dependent mediated by HSL (Sawada et al., 2004), indicating the 
involvement of this pump in cell-to-cell communication. This might contribute to the 
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pathogenicity of P. aeruginosa since QS governs many of the virulence factors (see 
section 1.1.4). It has been shown that in contrast to the wild type strain, P. aeruginosa 
lacking MexAB-OprM could not invade epithelial cells or kill leukocytes deficient 
mice (Hirakata et al., 2002). Chen et al. also described that MexAB-OprM can be 
activated in response to oxidative response sensed by MexR (Chen et al., 2008).  
  
17 | P a g e  
 
Table 1. RND efflux pumps in P. aeruginosa (Lister et al., 2009) 
Operon Components Function Regulators 
Substrates Intrinsic 
resistance 
# 
Antibiotics Additional compounds 
mexAB-
oprM 
MexA 
MexB 
OprM 
MFP 
RND 
OMF 
MexR* (-) 
NalD (-) 
NalC (-) 
Fluoroquinolones, β-lactams, β-lactams 
inhibitors, tetracycline, chloramphenicol, 
macrolides, novobiocin, trimethoprom, 
sulfonamides 
Biocides (e.g.triclosan), 
detergents (e.g. SDS), HSL, 
aromatic hydrocarbons 
Yes 
mexCD-
oprJ 
MexC 
mexD 
OprJ 
MFP 
RND 
OMF 
NfxB* (-) 
Fluoroquinolones,  
β-lactams, tetracycline, chloramphenicol,  
macrolides, novobiocin, trimethoprom 
Biocides (e.g.triclosan), 
detergents (e.g. SDS), aromatic 
hydrocarbons 
No 
mexEF-
oprN 
MexE 
MexF 
OprN 
MFP 
RND 
OMF 
MexT* (+) 
MexS  (-) 
MvaT  (-) 
Fluoroquinolones, chloramphenicol, 
trimethoprom 
Biocides (e.g.triclosan), aromatic 
hydrocarbons 
No 
mexXY 
MexX 
MexY 
OprM/Opm¤ 
MFP 
RND 
OMF 
MexZ* (-) 
Aminoglycosides, fluoroquinolones, β-
lactams, tetracycline, chloramphenicol, 
macrolides 
 
Yes 
mexJK 
MexJ 
MexK 
OprM/OpmH 
MFP 
RND 
OMF 
MexL* (-) 
Tetracycline, 
erythromycin Biocides (e.g.triclosan) 
No 
 
mexGHI-
opmD 
MexG 
MexH 
MexI 
OpmD 
? 
MFP 
RND 
OMF 
SoxR* (+) Fluoroquinolones 
Vanadium 
n.i. 
mexVW 
MexV 
MexW 
OpmE 
MFP 
RND 
OMF 
n.i. 
Fluoroquinolones, chloramphenicol, 
Tetracycline,erythromycin  
n.i. 
18 | P a g e  
 
mexPQ-
opmE 
MexP 
MexQ 
OpmE 
MFP 
RND 
OMF 
n.i. 
Fluoroquinolones, tetracycline, 
chloramphenicol,  
macrolides 
 
n.i. 
mexMN 
MexM 
MexN 
OprM 
MFP 
RND 
OMF 
n.i. 
Chloramphenicol, 
thiamphenicol  
n.i. 
triABC 
TriA 
TriB 
TriC 
OpmH 
MFP 
MFP 
RND 
OMF 
n.i.  
Triclosan 
n.i. 
czrCBA 
CzrB 
CzrA 
CzrC 
MFP 
RND 
OMF 
CzrS*(+) 
CzrR*(+) 
 
Cadmium, zinc 
n.i. 
PA2525-
PA2528 
PA2528 
PA2527 
PA2526 
PA2525 
MFP 
RND 
RND 
OMF 
n.i.  
n.i. 
n.i. 
*, major regulators that are located adjacent upstream of the operons. 
(+) and (-) indicate positive or negative regulation. 
n.i., not identified 
¤, MexXY can use OpmB, OpmG, OpmH and/or OpmI as OMFs. 
HSL, homoserine lactones 
#, If an efflux pump contributes to intrinsic resistance, it has impact on wild-type susceptibility when the encoding genes are disrupted. 
  
19 | P a g e  
 
1.1.2.1 P. aeruginosa resistance to β-lactams 
β-lactams (cefepime, ceftazidime, piperacillin-tazobactam, aztreonam ect.) are the 
oldest but still widely used antibiotics. The most common mechanism to become 
resistant to β-lactams is to express AmpC β-lactamase.  In P. aeruginosa AmpC β-
lactamase is expressed in a basal level and can be induced by β-lactams to a certain 
level. This is the main contributor of inherent resistance to β-lactams (Livermore, 
1995). The expression of ampC is positively regulated by a transcriptional regulator 
AmpR and repressed by AmpD, AmpDh2 and AmDh3 (Juan et al., 2006, Kong et al., 
2005). Mutations in ampD homologues can lead to stepwise derepression of AmpC 
and high resistance to all β-lactams except carbapenems (Juan et al., 2006). Recently a 
new β-lactamase PoxB was discovered to be responsible for β-lactams resistance 
when AmpC is deficient (Kong et al., 2005). Efflux pump MexAB-OprM is 
constitutively produced under normal lab conditions and provide impermeability of a 
wide range of antibiotics, including β -lactams. It has also been found in CF isolates 
that modification in penicillin binding proteins (PBPs) could lead to β-lactams-
resistance (Godfrey et al., 1981). 
Carbapenems including imipenem, doripenem, meropenem, etc. belong to a class 
of β-lactams that are highly resistance to β-lactamases. P. aeruginosa carries a 
substrate-specific porin OprD that facilitates the uptake of basic amino acids and 
carbapenems (Trias & Nikaido, 1990b, Trias & Nikaido, 1990a). OprD-deficient 
mutant P. aeruginosa displayed significantly increase of resistance to carbapenems 
(Sakyo et al., 2006).  
1.1.2.2 P. aeruginosa resistance to aminoglycosides  
Aminoglycosides (AGs) are a broad spectrum of antibiotics targeting ribosome and 
impairing bacterial protein synthesis (Davies et al., 1965). P. aeruginosa can become 
resistant to AGs like tobramycin and gentamicin by modifying the drugs through 
enzymes, such as aminoglycoside phosphoryltransferase APH (Zeng & Jin, 2003), 
aminoglycoside acetyltransferase (AAC),  aminoglycoside phosphoryltransferase 
(APT) and aminoglycoside nucleotidyltransferase  (ANT) (Mingeot-Leclercq et al., 
1999); APH is located in the chromosome (encoded by PA4119)  whereas the latter 
three families were found only in imported plasmids.  
In additional to aminoglycoside-modifying enzymes, P. aeruginosa can gain 
resistance to AGs by methylation of the 16s rRNA. Currently 5 ribosomal 
methylatransferase enzymes (RmtA, RmtV, RmtC, RmtD, and ArmA) have been 
found in clinical P. aeruginosa isolates and they are encoded by genes associated with 
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mobile genetic elements (Galimand et al., 2005, Lister et al., 2009, Wachino et al., 2006a, 
Wachino et al., 2006b, Yokoyama et al., 2003).  
Furthermore, aminoglycoside response regulator (encoded by PA2818_arr) is 
involved in tobramycin induced biofilm formation through c-di-GMP (Hoffman et al., 
2005). Induction of efflux pump MexXY-OprM is also involved in AGs resistance. The 
most frequently found AGs resistant clinical isolates contain a mutation in MexZ, 
which is a repressor of MexXY (Vogne et al., 2004).  
1.1.2.3 P. aeruginosa resistance to fluoroquinolones 
Fluoroquinolones like ciprofloxacin are another group of commonly used antibiotics 
that prevent DNA unwinding and duplicating. Mutations in DNA gyrase (gyrA, gyrB) 
and topoisomerase (parC, parE) exibit increased minimum inhibitory concentration 
(MIC) of P. aeruginosa to these drugs (Akasaka et al., 2001). We can see in Table 1 that 
fluoroquinolones are common targets of most of the RND efflux pumps. 
Overexpression of efflux pump system MexEF-OprN can induce resistance to 
quinolones (Kohler et al., 1997, Sobel et al., 2005). MexEF is repressed by MexS and 
positively regulated by MexT (Sobel et al., 2005). Normally elevated expression of 
MexEF in a mexS mutant requires active MexT (Maseda et al., 2000). MexCD-OprJ is 
another efflux pump system that can extrude various antibiotics including 
fluoroquinolones. Expression of mexCD-oprJ is negatively regulated by product of 
gene nfxB, located upstream of mexCD-oprJ.  Several kinds of nfxB mutants have been 
reported to be responsible for induction of mexCD-oprJ and resistance to 
fluoroquinolones (Jakics et al., 1992, Masuda et al., 1996, Poole et al., 1996). 
1.1.2.4 P. aeruginosa resistance to cationic antimicrobial peptides  
Cationic antimicrobial peptides (CAPs) such as colistin are often used to treat infection 
in CF patients. The positively charged (+5) colistin targets the negatively charged 
lipopolysaccharide (LPS) by electrostatic interactions (Hancock & Chapple, 1999). 
This leads to increased permeability of the outer cellular membrane, inducing both 
leakage of cell contents and self-promoted uptake of colistin to the periplasm (Falagas 
& Kasiakou, 2005). 
In P. aeruginosa, resistance to colistin is accomplished by adding aminoarabinose 
to lipid A moieties of LPS (Moskowitz et al., 2004). This results in a less negative 
charge of outer membrane and renders the drug action. Modification of lipid A is 
carried out by the products of arnBCADTEF operon. In the presence of CAPs or low 
Mg2+ condition, two independent two-component-systems, PhoPQ and PmrAB, 
positively regulate the transcription of their respective operons as well as the arnB 
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operon (Figure 3). There is interplay of the two systems as well as cross-talks with 
other unknown regulators (McPhee et al., 2003). Mutations in pmrB that cause 
constitutive expression of the response regulator pmrA and arnBCADTEF operon are 
often found in clinical isolates resistant to colistin (Moskowitz et al., 2004).  
 
 
Figure 3. Regulation of arnBCADTEF operon and CAPs resistance (Gooderham & Hancock, 
2009). PhoQ and PmrB senses Mg2+ limitation or CAPs and then activate their respective 
response regulators PhoP and PmrA by phosphorylation and positively autoregulate the 
transcription of their respective operons, as well as the arnBCADTEF operon. ArnBCADTEF 
pathway catalyzed the modification of lipid A, which limits the interaction of LPS and 
CAPs. 
1.1.3 Quorum Sensing 
Quorum sensing (QS) is a process of bacterial communication using secreted signal 
molecular called autoinducers. It is widespread in bacterial world and can occur 
within one species and between two species (Henke & Bassler, 2004). The 
concentration of extracellular autoinducer increases as the cells proliferate, and a 
large number of genes change their expression as a response when the autoinducer 
reaches a certain critical level (Henke & Bassler, 2004). 
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Figure 4. A simplified model of quorum-sensing in P. aeruginosa (Henke & Bassler, 2004). 
The las system (blue) and the rhl system (purple) are induced by their autoinducer 3-O-C12-
HSL and C4-HSL, respectively.  
P. aeruginosa possesses two major quorum sensing systems, both consisting of a 
transcriptional regulatory protein and its cognate autoinducer molecule. For one 
system, the regulatory protein is LasR and its cognate autoinducer molecule, N-(3-
oxododecanoyl)-L-homoserine lactone (3-O-C12-HSL), is produced by the signal 
synthase LasI. When bound by its cognate molecule (3-O-C12-HSL), LasR induces 
expression of a set of genes including lasI, which further increases LasI expression 
level and the production of 3-O-C12-HSL (Seed et al., 1995) (Figure 4). LasR also 
controls another QS system composed of the regulatory protein RhlR and its 
autoinducer, N-(butanoyl)-L-homoserine lactone (C4-HSL), which is synthesized by 
RhlI. The RhlR is bound by the autoinducer C4-HSL and activates its target genes in a 
similar way. The arrays of target genes of these two systems are partially overlapping. 
P. aeruginosa also possesses a third signal 2-heptyl-3-hydroxy-4-quinolone which is 
referred to as Pseudomonas quinolone signal (PQS) (Pesci et al., 1999) and it is also 
under the regulation of las and rhl systems.  
QS plays essential roles in various biological processes of P. aeruginosa. There 
were 77 QS regulated genes agreed by three independent microarray studies (Hentzer 
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et al., 2003). Its function in biofilm formation and virulence factors is best studied. 
Biofilm is a clump of cells growing as an organised community, commonly attached 
to surfaces (See 1.1.4.4). It has been shown that rhamolipid and extracellular DNA are 
controlled by quorum sensing and they are required for biofilm development (Davey 
et al., 2003, Allesen-Holm et al., 2006). QS also regulates a set of extracellular virulence 
factors, which will be mentioned in section 1.1.4.2. In rat models of P. aeruginosa lung 
infection, QS mutant gave rise to milder immune response and tissue damage 
compared to the wild type especially in chronic phase (Nelson et al., 2009, Wu et al., 
2001). 
1.1.4 Virulence factors 
P. aeruginosa is able to produce large variety of virulence factors (Figure 5) and their 
interactions lead to pathogenesis of P. aeruginosa and inflammatory responses of the 
host. Different roles of virulence factors are associated with different types of 
infections. Several major of virulence factors will be discussed here. 
 
Figure 5. P. aeruginosa virulence factors (Delden, 2004). 
1.1.4.1 Cell-associated virulence factors – Pili, Flagella, LPS 
Type IV pili are dynamic filaments that are able to attach to abiotic and biotic surfaces 
via the tips and move the cell by extending and retracting. Type IV pili mediated 
P. aeruginosa 
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motility is called twitching. Adherence of P. aeruginosa to epithelial cells is mainly 
mediated by type IV pili (de Bentzmann et al., 1996a, de Bentzmann et al., 1996b). 
Flagellum is primarily responsible for swimming motility and chemotaxis. It has been 
implicated in adhesion to mucin, the main component of mucus found on the 
epithelium surface (Feldman et al., 1998). FlhA, exporter of flagellar proteins is shown 
to be required in cell invasion (Fleiszig et al., 2001). Flagellum is also very 
immunogenic, inducing both inflammation and antibody response (Mizel et al., 2003, 
Ochi et al., 1991). P. aeruginosa LPS is also endotoxin as in the other Gram-negative 
bacteria. LPS contains a lipid A region, a central core oligosaccharide region and a 
repeating O-linked polysaccharide portion (Delden, 2004). There are two forms of the 
O-polysaccharide: A-band (homopolymer) and B-band (heteropolymer), while the 
latter one is highly immunogenic and associated with serum resistance (Rocchetta et 
al., 1999, Dasgupta et al., 1994).  
1.1.4.2 Secreted virulence factors 
Secreted virulence factors in P. aeruginosa normally cause tissue damage, bloodstream 
invasion and dissemination, which are typical pathogenesis for acute infection 
(Delden, 2004). Extracellular virulence factors include LasA and LasB elastases, 
exotoxin A, lipases, phospholipase C, protease IV, alkaline protease as well as 
rhamnolipids, pyocyanin, siderophores, hydrogen cyanide, etc. Most of them are 
controlled by quorum sensing circuit (Delden, 2004). QS signal 3O-C12-HSL itself can 
also induce various immune responses (Mizel et al., 2003). Pyocyanin as well as pili 
and flagellar is regulated in an RpoN (alternative sigma factor σ54, see 1.1.6) 
dependent manner (Hendrickson et al., 2001). Both lasR mutant and rpoN mutant have 
exhibited significantly reduced killing or injury in both Caenorhabditis elegans and 
mouse models (Rumbaugh et al., 2000, Hendrickson et al., 2001).  
1.1.4.3 Type III secretion apparatus 
Type III secretion system (TTSS) is found in wide range of Gram-negative pathogens 
and is responsible for the invasion and cytotoxicity of P. aeruginosa in mammalian 
cells (Yahr et al., 1997). TTSS injects exoproducts when contacting with target cells to 
elicit their toxicity at the infection site. The exoproteins, including exoenzyme S, 
exoenzyme T, exotoxin U and exoenzyme Y, are translocated and injected into host 
cells through complex machinery (Yahr et al., 1997). The genes encoding this 
machinery are clustered together in a locus termed exoenzyme S regulon in P. 
aeruginosa genome and the expression of these genes is controlled by the 
transcriptional regulator ExsA (Frank, 1997).  
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1.1.4.4 Biofilm 
Biofilm is matrix-enclosed microbial accretions that adhere to biological or non-
biological surfaces (Hall-Stoodley et al., 2004). The extracellular polymeric substance 
(EPS) matrix is usually composed of polysaccharides and DNA. Figure 6 illustrates 
biofilms growing in vivo and in lab settings. Biofilm formation is considered as a 
common growth mode of microorganisms in the environments. More importantly, it 
is associated with many bacterial infections such as Staphylococcus epidermidis 
colonization on implanted medical devices. In vitro studies revealed several 
important steps of biofilm development: initial attachment, microcolony formation, 
maturation and detachment, in which flagella, typeIV pili, QS, etc. are involved  
(Costerton et al., 1999). P. aeruginosa is an excellent biofilm former and the formation 
of biofilm has been considered as one of the key virulence factors in P. aeruginosa 
chronic infection (Figure 6). 
   
Figure 6. Biofilm in different environments. A) Scanning electron micrograph of S. aurus 
biofilm that developed on the distal tip of a cardiac pacemaker lead in a patient (Hall-
Stoodley et al., 2004). B) Scanning electron micrographs of a P. aeruginosa biofilm on the 
surface of a granite pebble with extracellular polymeric matrix shown (Whiteley et al., 
2001). C) Confocal micrograph of GFP tagged P. aeruginosa biofilm growing on a glass 
surface (Haagensen et al., 2007). Red: dead cells after colistin treatment.  
Biofilm associated infection is a big challenge in medical therapies (del Pozo & 
Patel, 2007). Figure 7 demonstrates a model explaining why forming biofilms can help 
bacteria persist better in the host. First of all, biofilm is more resistant to antibiotics 
than planktonic growing cells through multiple machanisms (del Pozo & Patel, 2007). 
Second, biofilms exhibit resistance to host phagocytic defences. For example, 
polymorohic neutrophils (PMNs) can not penetrate P. aeruginosa biofilm and the 
oxidative potential is reduced inside biofilms (Jesaitis et al., 2003). Phagocytic 
enzymes damage single bacterial cells and host tissues. Third, antibodies also fail to 
26 | P a g e  
 
penetrate EPS matrix and mediate opsonic killing of biofilm cells (Cerca et al., 2006, 
De Beer et al., 1997). 
 
 
 
 
 
 
 
 
 
Figure 7. Model of biofilm protection against antibiotics and immune attack (Costerton et 
al., 1999). Compared to planktonic cells, biofilm cells are better protected from antibodies 
and PMNs due to the penetration problem. They are also more resistant to antibiotics. 
Currently, studies of biofilm in vitro are mainly carried out in surface-associated 
devices with static or chemostat growth. However, to what extend these experimental 
settings can represent the in vivo situations is not known. The concept of biofilm has 
now expanded and cell aggregates that do not attach to any surfaces are also included 
since it is often found in vivo. For example, in a failed elbow arthroplasty case, 
clumps of S. aureus cells were mainly found in the joint fluid (Stoodley et al., 2008).  
We should be careful when extrapolate in vitro observations into in vivo studies. The 
life styles of bacteria can be incredibly different depending on specific diseases even 
though they are all called biofilms. 
1.1.5 Mucoid phenotype conversion and regulation 
Mucoid phenotype of P. aeruginosa is often seen in CF isolates but rarely in 
environmental isolates. It was regarded as a major hallmark of transition from 
intermittent colonization to a steady persistence (Pedersen et al., 1992, Govan & 
Deretic, 1996). Mucoidy is due to the massive amount of alginate produced from P. 
aeruginosa strains and slimy colonies are formed on agar plates (Figure 8). Alginate 
has been considered as one of the major virulence factors in CF infection. Emergence 
of the mucoid phenotype is associated with significantly increased rate in the decline 
in CF lung function (Henry et al., 1992).  The thick alginate layer might provide 
physical and chemical barrier to the bacterium to resist phagocytosis from 
macrophages (Oliver & Weir, 1985). 
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A    B  
Figure 8. Colonies of A) non-mucoid, and B) mucoid P. aeruginosa isolated from CF patients 
grown for two days on Luria–Bertani (LB) plates at 37 °C (this work). 
1.1.5.1 Alginate synthesis 
Alginate is a negatively charged linear copolymer of partially O-acetylated β-1,4-
linked D-mannuronic acid and its C5 epimer, α-L-guluronic acid (Linker & Jones, 
1966). The alginate synthesis pathway is illustrated in Figure 9. The alginates 
precursor guanosine diphosphate (GDP) mannuronic acid is synthesized from 
fructose 6-phosphate catalized by AlgA, AlgC and AlgD. This precursor is then 
polymized and transported across the inner membrance by a hypothized combination 
of alg8 and alg44 products (Ramsey & Wozniak, 2005). Some of the mannuronate 
residues are epimerized to guluronate residures by AlgG. AlgG, AlgK and AlgX 
might form a scaffold that protects the growing alginate polymer from being 
degraded by alginate lyase (AlgL) (Ramsey & Wozniak, 2005, Jain & Ohman, 1998, 
Robles-Price et al., 2004).  After epimerization, some of the mannuronate residues are 
acetylated at the O2 and/or O3 positions by AlgF, AlgJ and AlgI (Franklin & Ohman, 
2002). AlgE is an outer membrane protein that transports alginate polymer out of the 
cell (Rehm & Valla, 1997).  
1.1.5.2 Regulation of alginate synthesis 
Transcription of the alginate biosynthesis operon (algD-algA, PA3540-PA3551) is 
under the control of the algD promoter. Alternative sigma factor AlgT (also called 
AlgU, σ22) is the best known regulator that induces the algD operon transcription 
(Figure 10). The gene algT is located in an operon algT-mucABCD. The products of 
mucA and mucB bind and repress the AlgT protein. The mutation on mucA (or less 
often mucB) released the AlgT protein causing the conversion from nonmucoid to 
mucoid phenotype. Unlike other alginate genes, expression of algC is under the 
control of a two-component system response regulator AlgR, which is also activated 
by AlgT. AlgR also binds to algD promoter and cooperates with AlgT to bring a 
strong expression of algD operon (Govan & Deretic, 1996).   
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Figure 9. A model of alginate synthesis. A-X, 8 and 44 indicate AlgA, etc. I.M. and O.M. 
represent inner and outer membrane respectively. The letters G and M are guluronate or 
mannuronate, respectively. Ac is for acetyl group (Ramsey & Wozniak, 2005).  Alginate 
precursor GDP-mannuronic acid is synthesized from fructose-6-phosphate, and then 
polymized, partially epimerized, partially acetylated and finally exported. 
Besides AlgT, RpoN also plays roles in the activation of algD operon. Boucher et al. 
showed that RpoN is required for the mucoid phenotype in a muc23 background 
where there is no mutation in the algT-mucABCD region (Boucher et al., 2000); 
whereas in a muc22 background where mucA is mutated, RpoN acts as a repressor for 
initiation of algD transcription by AlgT. The muc22 strain does not produce 
significant amount of alginate in a nitrogen rich medium, but it is mucoid growing on 
alternative nitrogen sources, such as nitrate (Deretic et al., 1990). Boucher et al. showed 
that the repression is caused by antagonism of the two sigma factors RpoN and AlgT, 
due to the overlap of AlgT and RpoN promoters of algD gene. In nitrogen rich 
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condition, RpoN binds to algD promoter and inhibits its transcription regulated by 
AlgT; in nitrogen limited condition, RpoN is engaged in nitrogen response (see 
Section 1.1.6.2), therefore the repression is relieved and AlgT directed transcription 
initiates (Boucher et al., 2000).  
 
 
Figure 10. A classic model of alginate synthesis regulation (Govan & Deretic, 1996). The 
algD operon is positive regulated by AlgT, which is repressed by MucA (as well as 
MucB,C,D). AlgT induction could also lead to other effects such as oxidative stress 
responses. 
Another regulator AlgB (belonging to a subclass of NtrC family proteins which 
are usually RpoN activators) is also required in alginate production. Like AlgR, AlgB 
controls alginate levels by activating transcription of the algD operon and this process 
does not require phosphorylation even though it is a two-component response 
regulator (Feldman et al., 1998). Leech et al. showed that AlgB binds directly to algD 
promoter and stimulates transcription from the AlgT-dependent promoter, instead of 
RpoN promoter (Leech et al., 2008).  
Damron et al. proposed another model which involved not only AlgB or RpoN but 
also the cognate sensor histidine kinase of AlgB – KinB (Damron et al., 2009). In this 
model, it is not the mucA mutation but the AlgW-dependent MucA protolysis that 
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plays an essential role. AlgW is a homolog of DegS, a serine protease activated in 
response to unfolded outer membrane proteins in E. coli (Damron et al., 2009). KinB 
negatively regulates the alginate production. In a kinB mutant, AlgB and RpoN 
control the expression of factors which can activate the AlgW protease to release the 
repression of AlgT by MucA through proteolytix degradation and activate AlgT 
(Damron et al., 2009). 
Additionally, the alginate and motility regulator Z (AmrZ) was shown to activate 
algD operon and AlgT is required for its activity (Baynham et al., 1999). The promoter 
region of algD and binding sites of different regulators are shown in Figure 11, in 
which we can see the complexity of the regulation of algD operon.  
 
Figure 11. Binding sites of different regulators in algD promoter region (Baynham et al., 
1999). 
1.1.5.3 Pleiotropic effects of the algT activation 
Due to the fact that AlgT is a sigma factor, alginate synthesis is only a subset of 
downstream effects of algT activation. Comparison of global transcriptome between a 
non-mucoid CF isolates and its isogenic mucA- strain revealed that over 600 genes had 
significantly different expressions (p<0.05, fold change>2), including many genes that 
encode virulence factors, such as phenazine synthesis, rhamnolopid synthesis, Type 
III secretion system (TTSS), flagella biogenesis, and pili assembly, etc. (Rau et al., 2010). 
In accordance with these findings, it has been reported also that AlgT is a negative 
regulator of flagella synthesis (Garrett et al., 1999). Wu et al. showed TTSS is repressed 
in mucA mutant mediated by induction of AlgT and AlgR (Wu et al., 2004). To further 
clarify that the pleiotropic effects of mucA mutation are not the indirect consequences 
of over-production of alginate, Rau et al. also constructed an algD mutant in the mucA- 
background. The strain mucA-algD- showed a pronounced similarity in expression 
profile compared to mucA-, apart from genes directly involved in alginate synthesis 
(Rau et al., 2010). Phenotypically, both mucA- and mucA-algD- strains showed dramatic 
decline in motility, rhamnolipid secretion, C4-HSL production and killing of C. elegans 
compared to their non-mucoid parent strain (Rau et al., 2010). Pleiotropic effect of 
mucA mutation in reduction of virulence factor uncovered in these investigations has 
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important implications on P. aeruginosa pathogencity in chronic infections of CF 
patients. 
AlgT has a similarity of 79% in amino acid sequence to the heat-shock sigma 
factor σE in E. coli. Inactivation of algU decreases the P. aeruginosa survival rate when 
exposed to high temperatures and diminishes its resistance to superoxide-generating 
redox cycling compounds (Deretic et al., 1994, Yu et al., 1995, Govan & Deretic, 1996). 
Furthermore, expression of algU or mucoid conversion can be induced by 
environmental stresses such as heat shock (Yu et al., 1995) or hydrogen peroxide 
(Mathee et al., 1999).  Another sigma factor RpoH (σ32) involved in heat-shock 
response is dependent on AlgT as well (Figure 10).  
In conclusion, pleiotropic effects of algT activation in pathogenesis are mainly to 
reduce the virulence factors and enhance the resistance to oxygen radicals released 
from the immune system. In a study of CF isolates from 115 Scandinavian patients 
examing mucA and algT gene sequences, only 30% of them reverted due to algT 
mutation even though many non-mucoid CF isolates also carried mucA mutation; 
whereas 83% of in vitro derived spontaneous non-mucoid revertants have algT 
mutation (Ciofu et al., 2008). This indicates that a functional AlgT is essential for P. 
aeruginosa persistence in chronic CF infection. 
1.1.6 Global regulator RpoN  
We have mentioned previously about the role of σ factor RpoN regulation of algD 
operon in 1.1.5. RpoN was first reported playing essential role in nitrogen metabolism, 
later found to have global effects on many fundamental metabolic pathways and 
molecular functions. RpoN has not been investigated much for its role in P. aeruginosa 
pathogenesis. In 1994, some rpoN mutants were isolated from CF patients and 
defective rpoN gene was responsible for reduced swimming motility and resistance to 
nonopsonic phagocytosis in some of the isolates (Mahenthiralingam et al., 1994). 
RpoN mutants were also found in chronically infected patients in later CF studies 
(Smith et al., 2006).  
1.1.6.1 Control mechanism of RpoN activators 
In the transcription initiation, dissolvable σ factor associates with the core enzyme 
α2ββ’ω to form the holoenzyme of the RNA polymerase. Like Escherichia coli, P. 
aeruginosa has a major σ70 (RpoD) that controls a large number of housekeeping genes 
as well as several alternative σ factors controlling various genes in different 
conditions. RpoN, also called σ54, σN or NtrA, is one of the alternative σ factors but 
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with some unique features. First of all, unlike the other σ factors, RpoN is not 
homologous to σ70 (Merrick, 1993). Second of all, in contrast to σ70 like factors which 
are sufficient to initiate transcription by binding to the core enzyme, RpoN dependent 
transcription requires specific activators (Kustu et al., 1991). Third of all, the binding 
sites of those activators can be distantly (between 100 and 200 bp) upstream from the 
promoters that they regulate (Weiss et al., 1991).  
RpoN-dependent genes generally have conserved GG-N10-GC sequence located 
from -24 to -12 bp of the promoter region (Barrios et al., 1999). Once RpoN binds to the 
core enzyme, it needs to be isomerised to initialize the transcription process. The 
RpoN activators have ATPase activities and provide energy for the isomerisation of 
RpoN by ATP hydrolysis.  
The RpoN activators are composed of four domains, namely A, B, C and D from 
amino-terminal to the carboxy-terminal of the protein (Shingler, 1996).  A-domain is 
signal reception domain. There is little homology in A-domains of RpoN activators 
and they can be subgrouped depending on the modulation of activation signals. B-
domain is a short link (approx. 15 to 25 residues) between A-domain and the rest of 
the protein.  C-domain (also referred to the conserved σ54 activation domain) is highly 
conserved and involved in transcriptional activation. This domain is responsible for 
ATP hydrolysis and interaction with RpoN (Morett & Segovia, 1993).  D-domain 
contains a helix-turn-helix DNA binding motif, which is analogous to transcriptional 
activators and repressors (Shingler, 1996).  
In PAO1 genome, 22 probable RpoN activators that contain the conserved σ54 
activation domain (Pfam00158) were found using an online server ‘Integrated 
Microbial Genomes- Expert Review (IMG/ER) system’ (http://durian.jgi-psf.org/cgi-
bin/er/main.cgi) (Chaney et al., 2001, Studholme & Dixon, 2003).  Here we describe a 
few which have known functions associated with important roles of RpoN. 
1.1.6.2 NtrC and nitrogen metabolism 
RpoN was first identified to regulate nitrogen metabolism (Hirschman et al., 1985, 
Hunt & Magasanik, 1985). Besides nitrogen fixation microorganisms, the first step of 
nitrogen assimilation in most cells is to incorporate ammonia to amino acids, where 
glutamate and glutamine play pivotal roles. There are two pathways of ammonia 
assimilation (Figure 12). In the first pathway, glutamate is synthesized from ammonia 
by glutamate dehydrogenase (GDH). In the second pathway, one molecular of 
ammonia and glutamate are converted to one molecular of glutamine catalyzed by 
glutamine synthetase (GS), followed by formation of two molecules of glutamate 
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from one glutamine and 2 ketoglutarate, driven by the glutamate synthase (GOGAT). 
GDH pathway is employed in nitrogen-rich (low carbon/nitrogen ratio) environment 
due to the high affinity of GDH to ammonia, while the ATP-consuming GS-GOGAT 
pathway is more appropriate in nitrogen-limited (high carbon/nitrogen ratio, energy 
rich) environment since GS has a low Km for ammonia (Helling, 1994, Helling, 1998).  
Ammonia is virtually the preferred nitrogen source for all bacterial growth and 
provides highest growth rate than any other nitrogen sources. However bacteria often 
have to utilize alternative nitrogen sources such as amino acids, nucleosides and 
inorganic nitrogen sources (nitrite and nitrate), which is usually referred to nitrogen 
limited conditions. In such conditions, bacteria are induced explore maximal 
synthesis of GS and produce proteins that could transport and catabolise these 
alternative nitrogen sources. This nitrogen-limitation induced coordinated response is 
called nitrogen-regulated (Ntr) response (Reitzer & Schneider, 2001).  
 
 
Figure 12. Ammonia assimilation (Merrick & Edwards, 1995). Ammonia assimilation is 
carried out by GDH pathway in nitrogen rich condition and GS-GOGAT pathway in 
nitrogen limiting condition. 
In P. aeruginosa Ntr response is controlled by a four-protein-system through 
glutamine and GS (encoded by glnA gene): the uridylyltransferase (UTase)-uridylyl 
removing (UR) enzyme (encoded by glnD), a small trimeric protein, PII  (encoded by 
glnK), and a two-component regulatory system composed of the histidine protein 
kinase NtrB and the response regulator NtrC. In high glutamine conditions (nitrogen-
rich), UR is activated which prevents uridylylation of PII. Unmodified PII interacts 
with NtrB and stimulates the dephosphorylation of NtrC. The operon glnA-NtrBC is 
only expressed in a basal level. When glutamine level is low (nitrogen-limited), PII  -
UMP complex is formed and prevents the interaction between PII and NtrB. NtrB 
autophosphorolates and transferes the active phosphate group to NtrC. NtrC-P 
activates the expression of glnA-NtrBC operon through RpoN (Reitzer & Schneider, 
2001). A P. aeruginosa strain with deficient NtrC or RpoN is expected to grow 
defectively in low extracellular ammonia concentrations (nitrogen-limitation).  There 
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is a second regulation system of Ntr response in E.coli, Nac regulon. It works through 
σ70 dependent promoters but it does not have homologues in Pseudomonas (Li & Lu, 
2007).  
The mechanism of transcription activation of glnA promoter by NtrC in Salmonella 
typhimurium is illustrated in Figure 13. NtrC has two binding sites at -108 and -140 for 
dimers (A), which are very distant from the glnA RpoN promoter sequence (-12 and -
24). Phosphorylation and oligomerization of NtrC is required in the process (Porter et 
al., 1993). Phosphorylated oligomer of NtrC contacts RpoN-holoenzyme by means of 
DNA loop formation (B). NtrC then hydrolyzes ATP and catalyzes isomerisation of 
RpoN to open the closed complexes. The region around the transcriptional start site 
denatures and transcription is activated (C). 
Besides glnA, NtrC also regulates many other genes in E. coli in the similar way 
(Merrick & Edwards, 1995). Jones et al. identified at least 11 operons  or genes in 
Pseudomonas fluorescens Pf-5 having RpoN and NtrC binding sites in the upstream that 
are predicted to be involved in nitrogen assimilation, including glnA, ureE (Urease 
accessory pritein UreE), narX (Nitrate/nitrite sensor protein NarX) and PFL1000 (a 
putative amino acid transporter) (Jones et al., 2007). Those finding are in consistent 
with the poor performance of an rpoN knock-out strain utilizing nitrate, urea and 
many amino acids as nitrogen sources (Jones et al., 2007). 
1.1.6.3 CbrB and carbon metabolism 
Nishijyo et al. first discovered a two-component system CbrA-CbrB in P. aeruginosa 
that controls the catabolism of histdine and arginine (Nishijyo et al., 2001). Li et al. 
further characterized the interplay of CbrAB and NtrBC in the control of histidine and 
arginine operons (Li & Lu, 2007). They found that the growth of cbrAB mutant on 
arginine or histidine as sole carbon sources was abolished, while growth on the 
tricarboxylic acid (TCA) cycle intermediates was sustained.  An ntrB mutant that has 
a constitutive activation of NtrB in cbrAB mutant strain can restore the growth of 
arginie and histidine as carbon sources, but the capability of growing on TCA 
intermediates and glucose was compromised when ammonium is used as nitrogen 
source. This indicates that CbrAB and NtrBC form a network to control the C/N 
balance in P. aeruginosa (Li & Lu, 2007). 
In Pseudomonas, the products from a hut locus are responsible for histidine uptake 
and degradation. This locus was well described in Pseudomonas fluorescens SBW25 
strain (Zhang & Rainey, 2007).The homologs of P. aeruginosa were identified to be 
35 | P a g e  
 
coded by gene cluster PA5091 to PA5106 (Zhang & Rainey, 2007). Histidine is 
uptaken by a histidine transporter (encoded by hutT), and then degraded to 
glutamate, formate and ammonium by a five-step pathway catalyzed by enzymes 
encoded by hutUHIG and PA5106 (hutF). HutC is a local repressor of hut genes, but 
derepression of HutC is insufficient to activate the transcription of hutU operon 
(Zhang & Rainey, 2008).  
 
 
Figure 13. RpoN activation by NtrC (Porter, 1995). NtrC forms oligomer and binds to the 
glnA promoter. The NtrC oligomer then contacts RpoN and catalyzes its isomerisation by 
ATP hydrolysis. A localized denaturation around transcription start site occurred to initiate 
transcription.    
Zhang et al. demonstrated the regulation of histidine utilization in P. fluorescens 
SBW25 (Zhang & Rainey, 2008). When histidine is the sole carbon source, 
transcription of hutU operon is initiated from a σ54-type promoter and CbrB is the 
activator; when histidine is the sole nitrogen source, hutU operon is transcribed from 
a σ70-type promoter. The exact mechanism of the latter one is not known, but neither 
CbrB nor NtrC is required.  They also showed that CbrAB is capable of maintaining 
hut activity across a wide range of C:N ratios, while NtrC is only involved in hut 
activation in high C:N ratio (Zhang & Rainey, 2008). This regulation network is very 
different from other bacteria. In enteric bacteria, histidine is degraded by a four-step 
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pathway into glutamate and formamide. The extra step which converting formamide 
to formate and ammonium enables Pseudomonas to extract carbon from histidine 
more sufficiently, with more ammonia produced as well. Even though the 
accumulation of ammonium will inactivate NtrC, CbrB can still regulate the 
transcription of hut operon. This indicates the existence of CbrAB is an adaptive 
advantage for Pseudomonas to utilize various nutrients in the environments.  
Besides histidine, CbrB also regulates the metabolism of arginine in P. aeruginosa. 
In aerobic conditions, arginine is transported into cells via an ABC transporter system 
encoded by the aotJQMJ genes and converted to glutamate by the arginine 
succinyltransferase (AST) pathway encoded by the aruCFGDBE genes (Li & Lu, 2007). 
The arginine-specific regulatory protein ArgR is essential for the activation of both 
aot-argR and aruC operons, whereas the aotJ promoter also depends on CbrB and 
RpoN (Nishijyo et al., 2001).  
A cbrB mutant of PAO1 is also unable to grow on proline as sole carbon and 
nitrogen sources. However, this is not caused directly by failure of transcription 
activation in which CbrB and RpoN are involved, but by metabolic block elsewhere 
(Nishijyo et al., 2001). 
1.1.6.4 FleQ, FleR and flagellar synthsis 
Transcriptional regulator FleQ and two component system FleSR are adjacent in the P. 
aeruginosa genome. FleQ and FleR are RpoN activators and they control the 
expression of most of the flagellar synthesis genes. Dasgupta et al. proposed a model 
of regulatory circuit of flagellar biogenesis in PAK strain (Dasgupta et al., 2003), 
illustrated in Figure 14.  FleQ is the master regulator that directly or indirectly 
controls the expression of the majority of flagellar gene promoters except fliA 
(Dasgupta et al., 2003). FleQ and RpoN directly regulate the transcription of structural 
genes fleEFGHJ, glhA, flgG and fliLMNOPQRflhB, encoding proteins forming the basal 
body, MS ring, P ring, motor, switch, flagellar export apparatus and the filament cap. 
FleQ also regulates four regulatory genes, flhF (determines the flagellar localization), 
fleN (crucial in maintaining a single flagellum) and fleSR. FleR and RpoN activate the 
genes that encode the basal body-rod, L ring, hook, hook-cap scaffold and hook 
filament junctional proteins. A P. aeruginosa mutant of RpoN does not express 
flagellin genes(Totten et al., 1990).  
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Figure 14. Flagellar synthesis and regulation (Dasgupta et al., 2003). FleQ and RpoN are 
involved in regulation of most of the flagellum genes.  
1.1.6.5 PilR and pili synthesis 
Type IV pili are required for microbial adhesion on plastic surfaces and host cells, as 
well as movement based on pili retraction (twitching). There are many genes involved 
in pili assembly and regulation in P. aeruginosa. One major component of the type IV 
pili is pilin, encoded by pilA gene.  The transcription of pilA is controlled by RpoN 
and two component system PilSR, while PilR is an RpoN activator (Hobbs et al., 1993, 
Boyd et al., 1994). An RpoN mutant is not able to assemble pili or adhere to 
epithelium (Ramphal et al., 1991, Simpson et al., 1992, Ishimoto & Lory, 1989) . 
1.2 Cystic Fibrosis and pathogenesis 
1.2.1 Cystic Fibrosis 
Cystic Fibrosis (CF) is a life threatening genetic disease that affects about 70,000 
children and adults worldwide (www.cff.org). It is most common in Caucasian 
populations. In 1997, the incidence is 1: 3300 in Caucasians in United States, and only 
1:15300 and 1:32100 in African Americans and Asian Americans, respectively 
(Strausbaugh & Davis, 2007). In 2008, the median predicted age of survival is 37.4 
years (www.cff.org). The cause of CF was identified in 1989 to be mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene, located in 
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chromosome 7 (Kerem et al., 1989, Riordan et al., 1989). The most common mutation in 
CFTR gene is an in frame deletion of a phenylalanine at position 508, known as ΔF508, 
with a frequency of 80% in Danish CF patients and 70% worldwide (Collins, 1992, 
Koch & Hoiby, 1993).  
CFTR gene encodes AMP-dependent chloride channel which controls the passage 
of chloride ions in and out of the cell membrane. When a cell is stimulated to secrete, 
Cl- channels open allowing Cl- to pass through the membrane down its 
electrochemical gradient. Na+ ions follow the Cl- ions through a paracellular pathway, 
and water follows the salt due to the osmotic gradient (Lyczak et al., 2002). CFTR is 
mainly expressed in epithelial cells in respiratory, gastrointestinal, hepatobiliary and 
reproductive systems. Thus, CF is a multisystem disease characterized by GI and 
nutritional abnormalities, salt loss syndromes and male urogenital abnormalities, but 
the major clinical problem for CF patients is chronic pulmonary disease 
(Campodonico et al., 2008). In the lung, CFTR is distributed both in the conducting 
zone (consisting bronchioles) and respiratory zone (consisting alveolar)(Engelhardt et 
al., 1994) (Figure 16). Mutated CFTR results in unbalanced ion composition of 
epithelial cells secretion and dehydrated thick mucus accumulation (Sanders et al., 
2000). Impaired pulmonary defense leads to colonization of pathogenic microbes in 
the lung, which causes inflammation, scaring of lung tissues, insufficient air exchange 
and gradual reduction of lung function. The detailed mechanism of pathogen 
colonization and infection progression is discussed in section 1.2.3. 
1.2.2 Pathogenesis of CF lung infection 
Figure 15 shows the prevalence of the major bacterial pathogens in relation to age in 
CF patients, including P. aeruginosa, Staphylococcus aureus, Methicillin-resistant 
Staphylococcus aureus, Haemophilus inﬂuenzae, Burkholderia cepacia complex, and 
Stenotrophomonas maltophilia. S. aureus and H. inﬂuenzae are the most common bacteria 
species found in infants and CF children. Their role in the pathogenesis in CF patients 
is still not clear, but it has been proposed that they might damage the epithelium 
surface, leading to better attachment for P. aeruginosa (Campodonico et al., 2008, 
Lyczak et al., 2002). 
P. aeruginosa is considered as the most crucial pathogen in CF patients. Up to 80% 
of the adult patients carry P. aeruginosa (Figure 15). The presence of P. aeruginosa in 
the respiratory tract and the inﬂammatory responses it leads to are associated with 
increased rate of deterioration of lung function and risk of death (Campodonico et al., 
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2008, Li et al., 2005). A CF sputum sample can have up to 109 P. aeruginosa cells per ml 
(Hoiby, 1998). It is not clear why P. aeruginosa in general can proliferate better than 
other bacteria in CF lungs. One explanation is that wild type CFTR can bind to P. 
aeruginosa specifically and mediate an inflammatory response to eliminate infecting 
organisms, but this elimination process is impaired in CF patients (Campodonico et al., 
2008). There are also evidences that P. aeruginosa can repress the growth of 
Staphylococcus spp. in vitro or in vivo (Mashburn et al., 2005, Qin et al., 2009). 
 
 
Figure 15. Prevalence of the major bacterial pathogens in CF patients in relation to age 
(Goldberg, 2010). P. aeruginosa is the most frequent pathogen found in adult patients. 
Recent studies using non-culture detection methods have identified new bacteria 
species that could be potential pathogens, including some anaerobes (Harris et al., 
2007). Besides bacteria, eukaryotic microbes like Aspergillus spp are often isolated 
from CF sputum. Many different viruses have also been detected in CF patients, such 
as respiratory syncytial virus and influenzae A and B (van Ewijk et al., 2005). Bacterial 
phages also draw attention to researchers to understand the bacteria physiology in CF 
lungs. It is now generally appreciated that the CF airway is a complex and diverse 
ecosystem and investigation of the interaction of different microorganisms in the 
context of lung environment will contribute significantly to our knowledge of 
infection in CF patients. 
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1.2.3 CF lung environments – indications of selective stresses for bacteria 
adaptation 
The human lungs contain the conductive zone and the respiratory zone (Figure 16). 
The conductive zone, which is 5% of the total lung volume (about 150 ml), includes 
the trachea, bronchi, and terminal bronchioles (Hoiby, 2006). The epithelium of this 
zone contains mixed ciliated and non-ciliated cells in a firm layer. Conductive zone  
 
Figure 16. Conductive and respiratory zone of the lungs (Hoiby, 2006) 
produces mucus, which is a thin layer of 1-2% aqueous solution of mucins, enzymes, 
bacteria cells and products, antibacterial agents, cell debris from both bacteria and 
immune cells such as DNA and other mediators and proteins. Mucins are high 
molecular weight glycoproteins secreted from epithelial goblet cells and mucosal cells 
of submucosal glands. In healthy individuals, mucins are the main contributors of 
moderate viscosity of mucus. Inhaled particles or bacteria are trapped in mucus and 
exported from the airway by beating of the cilia (forming sputum), a process termed 
mucociliary clearance, which is the first line of pulmonary defense against microbial 
pathogens. CF patients on the other hand, have much more viscous mucus due to 
dehydration and more importantly, massive amount of DNA released from the cell 
debris. Cilia can not beat sufficiently to remove the mucus layer and impaired 
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pulmonary defence leaves a chance for microbial colonization. DNase is often used in 
clinic to reduce the viscosity of mucus for better air flow in the conductive zone.  
Figure 17 illustrates that P. aeruginosa cells form clumps embedded in the thick 
mucus intraluminally (not attached to bronchial wall or epithelial tissue) (Bjarnsholt 
et al., 2009, Worlitzsch et al., 2002). Even though there is an arterial blood supply from 
the aorta, the conductive zone is generally regarded as anaerobic or microaerobic for 
bacteria growth in the thick mucus layer (Worlitzsch et al., 2002). Nitrate which is an 
electron receptor for P. aeruginosa anerobic growth was found also in sputum samples 
with sufficient concentration to support the growth (Palmer et al., 2007).  
 
 
Figure 17. Thin section of an obstructed CF bronchus, stained with hematoxalin/eosin 
(Worlitzsch et al., 2002). Black arrow indicates the absence of P. aeruginosa on epithelial 
surface and white arrows show the presence of P. aeruginosa macrocolonies within 
intraluminal material. The blue gap is an artifact due to fixation. Scale bar: 100 µm.  
The nutrient supply in the mucus is mainly from cell lysate of immune cells, 
epithelial cells, lung/blood tissues or bacteria and considered to be rich. A study 
analyzing the components of CF sputum samples revealed that amino acids are 
abundant in the mucus (Palmer et al., 2007). It has been shown recently that alanine is 
a preferred carbon source, but the study was performed using a lab strain instead of 
adapted CF isolates (Boulette et al., 2009).  A microarray study directly on sputum 
samples demonstrated un-regulation of genes related to degredation of 
phosphatidylcholine (lung surface liquid molecues), indicating lung surface liquid 
might serve as another nutrient (Son et al., 2007). 
The respiratory zone which accounts for 95% of the lung volume (around 3000ml) 
contains respiratory bronchioles, alveolar ducts and sacs, but no cilia or submucosal 
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glands (Hoiby, 2006). The respiratory zone has venous blood passing through the 
capillaries of the aveoles and is considered as an oxygen rich niche for bacteria 
growth. But if the mucus blocks the air flow, the oxygen concentration drops in the 
respiratory zone. Chronic infection of bacteria in respiratory zone is usually 
associated with more severe lung destruction than infection in only mucus in 
conductive zone. Even in patients who have no persistence of P. aeruginosa within the 
respiratory zone, alveoli can still be damaged due the intensive immune response 
against P. aeruginosa attack.  
When nebulized tobramycin or colistin is inhaled by the patients, the 
concentrations of the drugs can be very high in the conductive zone, but low in the 
respiratory zone. However, if the intravenous course is administrated, concentrations 
of antibiotics are high in respiratory tissues but low in sputum (Hoiby, 2006). A 
microscopy investigation of lung tissue specimen and sputum samples from the 
Copenhagen CF centre showed that inhaled antibiotics can reduce but not eradicate 
the bacteria in the conductive zone; intravenous antibiotics administration on the 
other hand efficiently protects the respiratory zone from massive bacteria 
colonization (Bjarnsholt et al., 2009). Fixed lung material from patients who died 
before intensive treatment was introduced in the 1970s was preserved and examined 
as well. The results showed that both conductive and respiratory zone (i.e., alveolar 
ducts and sacs) have abundant bacteria aggregates (Bjarnsholt et al., 2009). This 
indicates as least in the Copenhagen CF centre, where there is also centralized control, 
intensive chemotherapies and special strain dynamics (see section 1.2.4 and section 
1.3.3), mucus layer is the main reservoir for P. aeruginosa colonization and adaptation. 
Apart from disabled mucociliary clearance, CF patients have functional immune 
systems. Different immune defenses recruited include polymorphonuclear leukocytes 
(PMN), alveolar macrophages, and antibodies. When PMNs phagocytose bacteria, 
highly reactive oxygen species (ROS) are produced, which kill bacteria or induce 
mutations, as well as damage surrounding host tissues (Hoiby, 2006). PMNs can be 
rich in both conductive zone and respiratory zone.  
In conclusion, there might be different niches in the lung for bacteria colonization 
in CF lungs, but mucus layer in the conductive zone is one the most important ones 
where most of the CF studies focused on. Nutrients, oxygen concentration, antibiotics 
concentrations, immune defences, etc. could be important environmental factors that 
drive the adaptation of bacteria in the long term colonization in CF lungs. Some of 
these factors like nutrients might be relatively stable over time and similar between 
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individuals; while others like antibiotics concentrations can alter all the time and 
differ from different patients or clinics. These lung environmental clues must be taken 
into consideration when studying P. aeruginosa persistence in CF lungs. 
A lot of efforts have been put to make animal models that could mimic the human 
CF lung condition especially for chronic infection. CFTR knock-out mice and pigs 
have been generated to study CF. Due to the difference in genetic background, 
disruption of CFTR gene in pigs develop abnormalities in various organs that are 
much more similar to humans compared to mice, including lung pathology (Rogers et 
al., 2008a, Rogers et al., 2008b). But it is more difficult to perform studies with pigs 
than mice for obvious reasons. It is still remains to be investigated whether CFTR-/- 
pigs develop spontaneous lung infections and follow the same dynamic as the 
infection progresses as in humans. 
1.2.4 Copenhagen CF centre: strain collection, treatment and definition of 
infection phases 
Copenhagen CF centre was established in 1968 for centralized control and treatment 
of CF patients in Rigshospitalet (Copenhagen University Hospital) (Nielsen et al., 
1988). The patients were examined on a monthly basis for lung function, antibodies, 
microbiology of lower respiratory tract secretion, etc. The patients, since the year 1976, 
were administrated intravenous courses that last for 14 days every three months with 
selected combinations of antibiotics (normally one from β–lactams and one from 
aminoglycosides). After the year 1984, the patients also started to take daily treatment 
with ciprofloxacin combined with either inhaled tobramycin or colistin (personal 
communication with Dr. Helle Johansen). 
Pulse Field Gel Electrophoresis (PFGE) was used as a main typing method to 
study the epidemiology of chronic P. aeruginosa infection. Epidemic spread of multi-
resistant strains in the Copenhagen CF centre was reported and patients separation 
was introduced to prevent transmission (Pedersen et al., 1986). Since the year 1981, 
patients with positive bacterial colonization were separated from those without. 
Afterward, they were further segregated into several cohorts: intermittent infected 
patients, chronic infected patients, patients without P. aeruginosa, etc. This leads to a 
special strain dynamics in the Copenhagen CF centre, which is described in section 
1.3.3. 
Valuable P. aeruginosa isolates and documentation about the patients and in the 
Copenhagen CF centre were available since 1973. Normally one pair of mucoid and 
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non-mucoid colonies from one sample were stored, but sometimes more colonies 
were stored if different morphologies appeared. The storage of P. aeruginosa isolates 
was not done routinely but irregularly until 2005, when we started to freeze all the 
samples delivered to the clinic. Meanwhile the whole sputum samples have been 
stored instead of single isolates.  
P. aeruginosa colonization is used as an essential indicator of infection stages since 
it is the most prevalent pathogen in CF patients. Chronic P. aeruginosa lung infection 
is defined as persistent presence in the sputum culture of P. aeruginosa for at least 6 
consecutive months, or less when combined with the presence of two or more P. 
aeruginosa precipitins (Hoiby et al., 2005). This definition is proposed in the 
Copenhagen CF centre but used in other clinics as well. A period of intermittent 
colonization precedes the chronic lung infection and starts from the first positive P. 
aeruginosa cultivation from sputum (Figure 18). Intermittent colonization could last  
 
 
Figure 18. Infection stages of CF lungs. PA: P. aeruginosa. Intermittent colonization can be 
eradicated and patients can stay PA negative for a period of months or even years. This 
process repeats until chronic colonization is established. 
from several months to a couple of years and is typically characterized by repeated 
cycles of short colonization and eradication and each cycle is most often caused by 
different clones. This definition is stated from clinical point of view. How different 
infection phases correlate with detailed patterns of bacterial adaptation still needs to 
be determined. 
Since chronic colonization is impossible to eradicate, treatment of CF patients in 
their early age became an important window to delay the chronic infection and 
preserve the lung function. Early aggressive therapy using ciprofloxacin, colistin and 
tobramycin has successfully improved the survival of patients without serious side 
effects (Hoiby et al., 2005). Recently surgeries in sinus have been introduced to the 
Copenhagen CF centre to remove the visible colonized tissue/pus in the paranasal 
sinuses of CF children who have symptoms of sinus infection (Johansen et al. 
unpublished data). Since bacteria in the sinuses may have less risk of meeting 
negative 
1st positive PA 
Intermittent colonization Chronic colonization 
Consecutive PA 
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antibiotics and they can also be transported to the deep lower respiratory tract, one 
hypothesis is that they adapt prechronically in the sinuses and spread afterwards into 
the lung. Several investigations already support this hypothesis (Mainz et al., 2009, 
Hansen et al., unpublished data) and sinuses could be an important niche for P. 
aeruginosa adaptation. Sinus surgeries in the early stage of infection could be another 
effective way of preventing or delaying the chronic infection. 
In summary, there are four major features in the Copenhagen CF centre that are 
important in order to understand the later conclusions of P. aeruginosa infection. First, 
Copenhagen CF centre executes an intensive antibiotic chemotherapy (including 
intravenous courses) from early ages of the CF patients. This might induce more 
resistance of P. aeruginosa to antibiotics but keeps the lung functional for a longer time. 
This intensive treatment is not applied in many other CF clinics, where multi-
resistance is concerned more problematic. Second, CF patients in the same cohort 
have chances of strain transmission. Third, there are two phases of CF infection – 
intermittent phase and chronic phase. Finally, a unique collection of P. aeruginosa 
isolates and documents since 1970s allows us to study the epidemiology and 
adaptation dynamics. 
1.3 Motivation and strategy of the project 
1.3.1 Previous ideas and models about P. aeruginosa persistence 
Previous investigations of P. aeruginosa and CF infection were mainly focused on how 
virulence factors can cause inflammation and tissue damage, how transition to the 
mucoid phenotype provides advantages for the persistence, if biofilm growth mode 
determines the colonization and persistence, etc. More and more evidences show that 
classical virulence factors such as motility, QS, proteases, type III secretion, LPS, etc. 
are phenotypes that chronic CF isolates tend to loose (Lee et al., 2005, Hanna et al., 
2000, Hancock et al., 1983, Luzar & Montie, 1985). Virulence factors are mainly 
required in acute infection, but seemingly not in chronic infections (Nguyen & Singh, 
2006).  Converting to mucoid phenotype is occurring with high frequency and has 
been considered as a hallmark of chronic stage of the infection. However, there are 
patients who do not carry mucoid strains constantly and the key factor for these non-
mucoid strains to be successful colonizers is not known. It is also appealing to find 
out if mucoid and non-mucoid strains have some common pathways to adapt or they 
simply occupy different niches. 
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For a long time, biofilm has been accepted as a symbol of chronic infection 
(Furukawa et al., 2006). Biofilm formation can lead to multi resistance to antibiotics  
(Hendrickson et al., 2001) and some toxins required for acute infection such as TTSS is 
actually incompatible with biofilm formation (Kuchma et al., 2005). However, a study 
on the biofilm formation ability of longitudinal CF isolates showed that non-mucoid P. 
aeruginosa isolates exhibited abnormality in their biofilm development and generally 
reduced capacity of in vitro biofilm formation as the infection progressed (Lee et al., 
2005). Another study found that the lasR gene, a key player in P. aeruginosa biofilm 
development is frequently mutated in CF isolates (Smith et al., 2006). All these results 
suggest that even though biofilm might exist in the lung, it is not structured exactly 
the same as what we see in in vitro settings. If so, what is the real life style of these 
bugs in the CF infection? Is switching growth mode enough to explain the complexity 
of P. aeruginosa infection in CF? 
Several studies seeking CF specific features in genome contents have finished 
using whole-genome sequencing or DNA microarrays (oligonucleotide array). There 
were both gaining and loss of specific segments in different strains, but no shared 
patterns were found in chosen CF isolates (Mathee et al., 2008, Ernst et al., 2003).   
Although mutations in mucA and B-band O-antigen have been reported in many 
CF studies (Hancock et al., 1983, Luzar & Montie, 1985), the concept of ‘genetic 
adaptation’ was first brought to the study of P. aeruginosa in CF infection only in 2006. 
Smith et al. sequenced two genomes isolated from one patient at 6 months and 96 
months of infection (Smith et al., 2006). 68 mutations were found including a DNA 
mismatch repair gene mutS. They have also cross-checked 91 isolates from 29 other 
CF patients. The most common mutational targets are mexZ, a negative regulator of 
multi-drug efflux pump, and lasR, primary regulator of quorum sensing and many 
virulence-related genes. By tracing mucA mutation in intermediate isolates they 
discovered multiple lineages coexisting in the early stage of the infection. The major 
and most striking finding in this paper is that QS and virulence factors are selected 
against in the CF adaptation of P. aeruginosa.  
The outstanding work by Smith et al. provided important information about the 
adaptation and diversity of P. aeruginosa infection in CF patients, but further 
questions were also laid out in front of us. Since this study mainly covered the first 7.5 
years of the infection, where does the adaptation go as the infection progresses? Is 
there an ’optimum’ of the evolution?  If this is correct, is this ‘evolutionary optimum’ 
common in different patients or clinics? What is the impact of each mutation on the 
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adaptation? Does the evolution always proceed with the same rate? Since we do not 
know the epidemiology of the strains in this study, are there strain transmissions that 
could interfere with our analysis of the evolution?  We hope to be able to answer 
some of these questions in our study. 
1.3.2 Molecular epidemiology and dynamics of P. aeruginosa isolates from 
the Copenhagen CF centre 
The ground work of this thesis was done by Jelsbak et al who investigated the 
epidemiology of P. aeruginosa populations in the Copenhagen CF centre using single-
nucleotide polymorphism (SNP) typing tool – AT biochip (Clondiag Chip 
Technologies, Germany). A large amount of isolates from both chronic and 
intermittent patients were studied.  
High genotype diversity was found in intermittently colonized patients and 
recently diagnosed chronically infected patients. Most of those patients acquire 
unique clones from the environment. Early aggressive chemotherapy can temporarily 
remove these bacteria but re-colonization by identical or different clones occurred 
later (Jelsbak et al., 2007).  
In contrast, there is very low genotype diversity among CF patients with long-
term chronic infection. The distinct and dominant clones (r and b) were identified and 
they have been present and transmitting among different patients for about thirty 
years (Figure 19). The transmission is most likely because these patients with chronic 
infection were centralized for treatment as a cohort in the Copenhagen CF clinic.  
The two dominant clones have evolved into highly successful colonizers of CF 
patients and they are capable of out-competing other strains including environmental 
strains. The study also showed that virulence factors or conversion to mucoid 
phenotype play minor roles in the persistence and transmission of these two 
dominant clones (Jelsbak et al., 2007). The pathways that are really involved in the 
development of persistence of successful P. aeruginosa colonizers still need to be 
identified.  The parallelism or divergence of the same genotype in different patients is 
also an essential question to answer. It is also not clear how and when the dominant 
clones developed and started to spread in the clinic. 
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Figure 19. Genotyping of longitudinal P. aeruginosa isolates from patients with long-term 
chronic infection. Labeled boxes under the strain names specify that genotypes of the 
strains. White boxes specify unique genotypes found only once in the data set. Asterisks 
indicate mucoid isolates. The results of sequence analysis of mucA and algT compared to 
PAO1 from selected isolates are shown in black and white text, respectively (Jelsbak et al., 
2007). 
1.3.3 Inspirations from experimental evolution research on microorganisms 
Considering P. aeruginosa infection as an evolution process in the CF lung, it is of 
great interest to get inspired from experimental evolution studies. Experimental 
evolution on microorganisms allows us to observe ’real-time’ phenotypic and genetic 
changes in details in a relatively short time period. One of the pioneers in this field is 
Richard Lenski and colleagues, who initiated a long-term evolution experiments in E. 
coli (LTEE) since 1988. These experiments provided tremendous quantitative data 
clarifying previous evolutionary theories and addressing new insights that are still 
being investigated. The LTEE setting is shown in Figure 20, where twelve populations 
of E. coli B strains were propagated in a glucose limiting condition for over 40,000 
generations by serial transfer. Each 24-h growth cycle allowed ~6.6 bacterial 
generations. Each day, the evolving cell populations experienced lag phase, 
exponential growth, decelerating growth, and stationary phases as the total size of 
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each population fluctuated between 5  106 and 5  108 cells per 10 mL culture 
(Lenski et al., 1998). Six of the populations were founded from Ara- that is unable to 
utilize arabinose as a sole carbon source, while the other six were founded from an 
engineered isogenic strain Ara+. The arabinose-utilization serves as a marker in 
competition experiment for fitness measurement and it is selectively neutral under 
the selective conditions used in LTEE (Lenski et al., 1991).  
 
 
Figure 20. Long-term evolution experiments in E. coli. Ancestral E. coli strain was evolved 
in glucose limiting condition for more than 40,000 generations by serial transfer.  
Fitness was measured by competing the evolved strain and ancestral strain in the 
same environment where the evolution progressed. The two competitors were mixed 
at 1:1 ratio, diluted 100 fold and grown for 24 h. Initial and final densities were 
estimated by plating cultures on tetrazolium arabinose indicator plates. The growth 
rate of each competitor is calculated as the natural logarithm of the ration of its final 
density to its initial density (adjusted for dilution). Relative fitness is defined as the 
ratio of growth rates of the evolved and ancestral strains (Lenski et al., 1991, Elena & 
Lenski, 2003). Lenski and colleagues followed the dynamics of the evolution and 
examined the genetic bases of the adaptation. Here we summarized some of the main 
observations and conclusions. 
 
 
 
 
 
 
 
 
  
50 | P a g e  
 
 
 
 
 
 
 
 
 
Figure 21. Rates of mutation accumulation and fitness improvement. Blue circles show the 
total number of genomic changes relative to the ancestor in each sampled clone. The blue 
line represents a model where mutations accumulate uniformly over time. The light blue 
curves define the 95% confidence interval for this linear model. Green squares show the 
increase of this population’s mean fitness relative to the ancestor over time, and the green 
curve is a hyperbolic plus linear fit of this trajectory. Each fitness estimate is the mean of 
three assays; most of the spread of points around the fitness trajectory reflects statistical 
uncertainty inherent to the assays. The inset shows the number of mutations in the 40,000-
generation clone; the dashed curve approximates the change in the timecourse of genomic 
evolution after a mutator phenotype appeared at about generation 26,500 (Barrick et al., 
2009). 
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1. The fitness increases rapidly at the beginning and decelerate over time. This has 
been observed in other studies with viruses as well (Novella et al., 1995, Bull et al., 
1997).  In LTEE, E. coli strains gain most of the fitness in the first 2000 generations 
(Figure 21). The steep increase at the early stage of the evolution is not caused by 
larger amount of mutations but by very few mutations that have great impact on 
fitness improvement. In non-mutator strains, mutation accumulation is linear over 
time (Figure 21) (Barrick et al., 2009).   
2. Evolution creates specialists which are more fit in the selective environment but 
have reduced fitness in other environments (trade-off). Antagonistic pleiotropy, 
instead of mutation accumulation, was the main cause (Cooper & Lenski, 2000).  
Adapted E. coli populations have a decay of unused catabolic functions and this 
happened also early in the evolutionary process, which indicates pleiotropic effects of 
early mutations are playing important roles. Furthermore, unused catabolic functions 
in mutator strains do not decay more than non-mutators, suggesting the 
insignificance of mutation accumulation (Cooper & Lenski, 2000). 
Vocabulary box 
Fitness: Fitness is a measurement of the ability of organisms to survive and 
produce offspring in the environment they live (Orr, 2009). There are many ways 
of calculating fitness. In experimental microbial evolutionary, fitness of the 
evolved strain (i) relative to the ancestor (j) is measured by competing the two for 
time T in the environment where the evolved strain is derived from. The 
population size of the evolved strain increased from Ni (0) to Ni (T) and average 
increase rate (Malthusian parameter) is calculated as      TTNTNm iii ln . 
The relative fitness of the evolved strain to ancestral strain Wij is expressed as the 
ratio of the two Malthusian parameters, Wij = mi/mj. (Lenski et al., 1991, Elena & 
Lenski, 2003, Hansen, 2005). 
Antagonistic pleiotropy: Antagonistic pleiotropy arises from trade-offs, such that 
the same mutations that are beneficial in one environment are detrimental in 
another (Cooper & Lenski, 2000). 
Parallel evolution: Two or more lineages independently evolve similar or 
identical features (Cooper et al., 2003).  
Epistasis: Contribution of a mutation to an organism’s phenotype depends on the 
genetic background in which it occurs (Cooper, 2008). 
Historical contingency: Occurrence of certain mutation or phenotypic expression 
is contingent on prior mutations in the population (Blount et al., 2008).  
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3. Lenski and colleagues identified several same beneficial mutations occurring in 
many independent lineages, such as stringent response regulator spoT (Cooper et al., 
2003). Quantitative measurement of repeatable evolution changes and statistic tests 
pointed towards that parallel evolution was driven by selective force, rather than 
random mutations (Woods et al., 2006). Parallelism is strong indication of adaptive 
changes. 
4. Mutator mutations in DNA repair system increased mutation rate dramatically 
(Figure 21) but do not seem to confer any direct fitness advantage; instead, they might 
spread by hitchhiking with beneficial mutations (Sniegowski et al., 1997). 
5. Epistasis is important in the adaptive evolution. Compared to ancestors, the 
evolved strains have more genes changed their expression when deleting a central 
regulatory gene crp. There is also a striking degree of parallelism in the expression 
profile between the two independently evolved populations (Cooper, 2008).  
6. Historical contingency can contribute to innovative phenotypic changes in the 
evolution. A citrate-using variant (Cit+) appeared in the late stage. Citrate is a carbon 
source that E. coli can not use; it is added in the medium for checking contaminations. 
However, Cit+ variant evolved in one of the populations and extensively enhanced the 
fitness. ‘Replay’ of the evolution from different points of that population’s history 
showed that Cit+ did not rise before 20,000 generations, which indicate evolution of 
this phenotype was contingent on the particular history of the population (Blount et 
al., 2008).  
The LTEE settings are simple and allow bacteria to evolve in a homogeneous 
environment. In reality, the environment such as the CF lung is much more 
heterogeneous and bacteria could grow as structured communities rather than 
homogenous suspension. All these factors facilitate to generate much more complex 
and diverged phenotypic and genetic changes (Rainey & Travisano, 1998). However, 
with coughing, DNase treatment and occasional lung flushing of the patients, bacteria 
in different locations in the lung are geologically possible to meet and compete. 
Competition and replacement of strains as well as low diversity in genotypes in P. 
aeruginosa has further supported this possibility from previous study (Jelsbak et al., 
2007). This means even with complexity of the lung environment, bacteria can still 
grow in a relative homogenous fashion in large part of the lung and selective sweeps 
could still be one of the determining forces driving P. aeruginosa adaptation. In that 
sense P. aeruginosa evolution in CF lungs is very much comparable with E. coli 
evolution in test tubes.  
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We are also confronted with many problems when studying P. aeruginosa 
evolution in CF lungs. A crucial one is that we could not perform direct fitness 
measurement. There is no good animal model that could be used to mimic CF lungs 
and perform competition experiments (see 1.2.3). However, since it has been shown 
that parallel changes tend to have high fitness, we consider strains carrying many 
parallel traits and capable to transmit and out-compete others have higher fitness. 
One of the common changes in CF isolates is reduced virulence.  
Another very challenging problem is the strain transmission. The evolution 
process in one patient is disturbed when transmission happens, which is indeed the 
case for most of the patients. Furthermore, P. aeruginosa in CF lungs are confronted 
with very complicated and fluctuating selective forces, including antibiotics, immune 
defence, nutrients, etc., and a lot of them have not well described in molecular 
mechanisms. However, we hope to grab some essential clues in this project despite of 
all the uncertainties.  
1.3.4 Objectives and Strategies  
The major aim of the project is to identify and characterize the essential adaptation 
processes that are responsible for the chronicity of CF infection. Since we now know P. 
aeruginosa persistence involves genetic adaptation, how do we understand this 
microbial evolution process in the light of theories and models concluded from in 
vitro evolution? This goal will be achieved by 4 steps: 
1. Determine the growth activity of P. aeruginosa in CF lungs.  
2. Find out the overall evolutionary trajectory of P. aeruginosa adaptation in CF lungs. 
3. Identify important genetic changes that make the dominant clones successfully 
adapted. 
4. Investigate the diversity and parallelism of the evolutionary pathways.  
Why does growth rate matter? First of all, the growth dynamics uncovers the life 
style of P. aeruginosa in CF lungs, which is the first step to understand mechanisms of 
the persistence. For example, tuberculosis caused by Mycobacterium tuberculosis is also 
a chronic respiratory track infection. Bacterial persistence is the result of latent stage 
of M. tuberculosis with very low metabolic state (Hu et al., 1998, McCune et al., 1966a, 
McCune et al., 1966b). But in chronic gastritis infection caused by Helicobacter pylori, H. 
pylori has very active growth (Dubois et al., 2000). Knowing the growth activity is 
fundamental to understand the strategies of bacterial persistence. Besides, we can use 
the in situ growth rates to estimate the number of generations since the first 
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colonization, which is obviously a key parameter when microbial evolution is what 
we pursue. To measure the growth activity, we used fluorescent in situ hybridization 
(FISH) to look at the localization and growth rate of P. aeruginosa population from 
sputum samples. The principle of linear correlation between ribosome content per cell 
volume and specific growth rate in certain range has been used to determine growth 
rate of samples in complex environments (Cooper, 2008, Poulsen et al., 1995). Thus we 
can use FISH to quantify the ribosome content and estimate the in vivo growth rate of 
P. aeruginosa both in single cell level and distribution of growth activities of the 
bacterial population in CF sputum samples, which represent the lungs.   
To determine the important evolution pathways, systematic approaches such as 
whole genome sequencing, DNA microarray and Biolog Phenotype chip, etc. were 
applied and integrated data analysis was implemented to investigate the results. Here 
we mainly focused on one of the dominant clones, the b clone (Jelsbak et al., 2007) 
(Figure 19). Three strains will be fully sequenced: An intermittent b clone and two b 
type strains isolated from one chronic patient, p7, isolated in 1991 and 2007 (Figure 
19). In this way the whole infection time from intermittent to chronic phase was 
covered. Transcriptome profiles during growth in defined media were obtained from 
the selected dominant P. aeruginosa isolates as well as non-adapted isolates. Here we 
are not focusing on the global transcriptional responses of P. aeruginosa strains 
growing in mucus (sputum) media. Instead, we search for longitudinal and parallel 
changes of the expression patterns related to the adaptation. This was done just in lab 
media. Although standard lab media cannot resemble the lung environment, most of 
the effects of regulatory mutations can still be tracked. On one hand, we hope to find 
specific pathways or functions that are essential or targeted against during the 
adaptation. On the other hand, how evolution shapes the overall expression profiles 
over time might be used as an indicator of how much the strains have adapted. 
To compare what we find in genome and expression data, we also simultaneously 
characterized different phenotypes such as virulence factors, growth rates and 
antibiotics resistance patterns, as well as metabolism profiles using phenotype chips. 
Phenotype chip (Biolog) is also a high-through-put tool that can be used to check the 
growth potential on/with thousands of substrates, including nutrients, antibiotics and 
other toxins. We mainly focused on the catabolism of about 300 different carbon and 
nitrogen sources. Hopefully we could find correlations of genomes, transcriptomes 
and phenotype profiles in specific pathways and overall patterns related to the 
evolution processes.  
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Afterwards we tried to examine the extent of consistency and diversity of these 
clues in a bigger samples size. We also looked for if parallel evolution of the b clone 
happened in different patients to have a clearer view of how the b clone developed 
and spread in the whole clinic. We also compared these results with r clones using 
phenotypic assays and gene sequencing.  
In summary, there are several features that make our project unique and 
especially interesting: 
1. Experimental evolution with bacteria enabled us to study evolution lasting for 
thousands of generations. The longest experimental evolutionary study so far is the 
50,000 generations of reproduction of E. coli in Lenski’s lab initiated in 1988. The CF 
collection that we worked on represented the evolutionary time from 1973 until now, 
allowing over 150,000 generations of replication.    
2. In contrast to the defined lab conditions in experimental evolution, the CF airway 
is a natural system with many levels of complexity. It has spatial diversity in terms of 
different airway compartments but also mixing of population (e.g. by coughing). It is 
a dynamic (e.g. fluctuation in concentrations of antibiotics) and open system with 
occasional environmental invaders. It also has a jungle of many other microbial 
inhabitants co-existing. To make things even more complicated, the detailed 
conditions in the CF airways, such as nutrients, are not well understood. How much 
we can discover about bacterial evolution in such a natural system would be 
extremely intriguing and important. 
3. The study has a scope of large number patients in the cohort of chronically 
infected patients in the Copenhagen CF centre, instead of a few patients. Additionally, 
the history and epidemiology of P. aeruginosa has been well described previously 
(Jelsbak et al., 2007). We also have access to the information about treatment strategies, 
strain transmission and patient conditions.  
4. Contrary to a lot of previous reports which were case stories of specific changes in 
CF isolates, we have employed combined systematic approaches that enable us to 
discover not only specific pathways that are important to the adaptation but also the 
relations of CF isolates in a time dependent manner. 
Results produced from this project would be the first study revealing bacterial 
evolutionary details during chronic infection in humans. With integration of a variety 
of systematic approaches, we expect to provide new concepts and models of P. 
aeruginosa pathogenesis in CF infection, which could eventually lead to improved 
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treatment. These results would be of great significance for studying microbial 
evolution and other long-term infections. 
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Table S1. Growth rate and fluorescence data used in Figure 3 
Standard 
curve 
Strain Genotype Medium 
Specific 
Growth 
rate (h-1) 
Intensity/ 
Cell 
Volume 
C2 
p7 s1B1/05 b 
LB 0.61 350 
ABT+1%casamino acids and 
0.5%glucose 
0.42 240 
pig mucus medium 0.4 230 
ABT+10mM Sodium Citrate 0.28 150 
anaerobic growth 0.28 153 
p7 14429/91 b LB 0.81 455 
p11 s1E9/05 b 
LB 0.56 330 
ABT+1%casamino acids and 
0.5%glucose 
0.42 240 
ABT+10mM Sodium Citrate 0.34 180 
C1 
p11 s3A1/05 4 
LB 0.68 275 
ABT+1%casamino acids and 
0.5%glucose 
0.45 221 
ABT+10mM Sodium Citrate 0.24 176 
B4-1 unique 
LB 1.09 385 
ABT+10mM Sodium Citrate 0.77 283 
ABT+0.2%glucose 0.6 248 
p16 s1C7/05 r 
LB 0.65 298 
ABT+1%casamino acids and 
0.5%glucose 
0.4 222 
ABT+10mM Sodium Citrate 0.23 185 
p6 s1C3/05 unique 
LB 0.68 300 
ABT+1%casamino acids and 
0.5%glucose 
0.34 210 
ABT+10mM Sodium Citrate 0.22 170 
p2 s1F6/05 r 
LB 0.6 280 
ABT+2%casamino acids 0.42 220 
ABT+10mM Sodium Citrate 0.34 200 
PA01 unique 
LB 1.3 440 
ABT+10mM Sodium Citrate 0.8 320 
ABT+0.2%glucose 0.6 250 
PA14 unique 
LB 1.25 430 
ABT+10mM Sodium Citrate 0.82 330 
ABT+0.2%glucose 0.47 220 
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3.1 Abstract 
Microbial evolution studies in defined conditions have contributed significantly to 
our knowledge of the genetic basis of evolution. However, microbial evolution 
process occurring in a natural environment has never been reported due to the 
obvious complexity. Here we describe a unique case of long term microbial evolution 
in a natural environment – genetic adaptation of Pseudomonas aeruginosa in cystic 
fibrosis chronic infection since 1973. Thanks to an exceptional collection of sputum 
isolates derived from the Copenhagen CF clinic, it has been possible to follow the 
evolutionary process over a period of 35 years corresponding to more than over 
150,000 generations of bacterial growth. We focused on one cell-line, the lineage b that 
has been dominating and transmitting in many patients. Through systematic analysis 
of transcriptome data, genome sequences and metabolic profiles, we could estimate 
the evolutionary trajectory of this P. aeruginosa clone in chronic CF airways. The 
development of the b clone from the early stage of the infection to highly adapted 
stage has displayed a step-wise progression, in which major changes happened early 
in the evolution and these changes were mainly caused by very few mutations in 
regulatory genes. This early rush of the adaptation has allowed this particular clone 
to out-compete environmental strains and become dominant in many patients. All the 
different highly adapted P. aeruginosa exhibited similar patterns in terms of 
transcriptional and metabolic profiles, but distinct from early or environmental 
isolates. Besides, certain parallel evolution traits were also identified in phenotypic 
and genetic levels.  
3.2 Introduction 
Studies of evolution on microorganisms have received increasing attention, not only 
because many microbes develop close relations (beneficial or pathogenic) with human 
beings, but also because microorganisms have  great advantages for evolution 
experiments which allowed us to record on-going details of evolutionary progress 
which could shed light on the understanding of evolution in general. One of the 
pioneers in this field is the group led by Richard Lenski, who propagated 12 
Escherichia coli cultures for more than 40,000 generations in glucose minimal medium 
since 1988 (Lenski et al., 1991). From this long-term experiment, many fundamental 
questions of evolution process have been clarified and previous phenotypic 
observations have been quantified with genetic basis, including kinetics of fitness 
increase, examples of parallel evolution, prevalence of adaptive changes in global 
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regulatory networks, etc. (Cooper et al., 2003, Cooper & Lenski, 2000). However, these 
investigations were performed with isolated pure culture evolving in defined 
conditions. Test tubes are far from mirroring the complexity of natural environments. 
It is thus a very intriguing challenge to uncover the mechanisms of microbial 
evolution in ‘real-world’ cases, and assess the compatibility of these with current 
evolutionary theories drawn from experimental evolution studies. 
The specific model we chose was airway infection of the opportunistic pathogen 
Pseudomonas aeruginosa in cystic fibrosis (CF) patients, an infection which originates 
early in childhood and remains in patients for the rest of their lives. It is widely 
accepted that CF patients often acquire P. aeruginosa strains from various 
environmental reservoirs and the bacteria persist in CF airways through considerable 
genetic adaptation (Smith et al., 2006). The time point of the first acquisition of P. 
aeruginosa defines a reference point for all subsequent evolutionary changes as long as 
the same clone resides in the patient. In analogy with known examples of laboratory 
based evolution experiments, the chronic CF infections offer similar possibilities of 
sampling and characterization of the developing populations. The complexity of the 
patient airways (including the therapeutic measures taken by the medical staffs) is 
obviously far greater than the usual laboratory conditions and not well understood at 
the molecular level. However, the confinement of the bacteria to individual airway 
compartments in specific patients provides parallel opportunities for analysis of 
adaptive processes compared with those determined by laboratory settings.  
Although bacteria often have very short generation times allowing investigations 
of adaptation over hundreds or even thousands of generations, more substantial 
evolutionary changes may require tens of thousands or hundreds of thousand 
generations of growth. In many ways this reflects the general problem of many 
evolutionary studies, which have only been possible through findings of fossils in 
samples of known age. Here we took the advantage of a unique historical strain 
collection that contains huge amount of P. aeruginosa isolates from hundreds of 
patients in the Copenhagen CF clinic with 35 years of time span. Given that P. 
aeruginosa in chronic patients has a doubling time of 100-200 min on average (Yang et 
al., 2008), lapses of 35 years allow more than 150,000 bacterial generations, which 
concedes immense potential for genetic alterations. This collection covers the entire 
course of P. aeruginosa evolution since its early transition from environment to human 
lung until very late stage of the infection in which P. aeruginosa has highly adapted to 
the lung.  
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The population dynamics of P. aeruginosa in these patients have been thoroughly 
investigated and two distinct and dominant clones were identified in chronic patients 
(Jelsbak et al., 2007). The evolutionary triumph of these two clones was manifested by 
the fact that they have been able to successfully persist and transmit among patients 
for more than 2 decades (Jelsbak et al., 2007). The present study focuses attention on 
one of the 2 dominant clones. We applied systematic measurements of transcriptional 
and metabolic profiles of isolates with this genotype from different patients and 
demonstrated the portrait of a successful persister. Together with genomic mapping 
of specific targets, we managed to estimate the evolution trajectory of this clone in 
many CF patients over time and determine some of the crucial steps. Other aspects 
concerning parallel evolution were also illustrated in details.  
3.3 Results 
3.3.1 First glance of the evolutionary consequence: profound remodelling 
and loss of ID 
If bacteria migrate from natural environments (aquatic, terrestrial) to human internal 
environments in which they adapt over time, it is expected that the extensive switch 
in conditions will lead to substantial changes in life-style caused by numerous 
adaptive mutations. We assessed this expectation by performing diagnostic 
identification tests on a number of isolates of P. aeruginosa derived from different time 
points in infection in CF patients. Strains obtained from very early time points were 
unequivocally identified as P. aeruginosa using Biolog ID plates (see Material & 
Methods), whereas isolates with a history of more than 15 years of human airway 
colonization could not be identified at the species level (in some cases not even at the 
genus level). Thus, the overall phenotypes of isolates from chronically infected 
patients drift away from the normally conserved species specific profile, even though 
the genetic changes in the different cell lines may not be the same. This confirmation 
of the expected genome changes will be explored further in the following text.  
3.3.2 Our ‘fossils’ – strain collection 
In 1973 a ‘fossil’ collection of P. aeruginosa isolates from CF patients was initiated at 
the CF Clinic in Copenhagen, and subsequently isolates from many patients have 
been deposited in this collection, which today comprises many thousand strains. In 
the beginning the strains were stored as agar slants, later kept frozen at -80°C in 
glycerol. Like any fossil collection the CF isolates in the Copenhagen CF Clinic do not 
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constitute a complete coverage of all stages of evolutionary development. Some of the 
isolates (mainly the earliest ones) were not kept under optimal conditions and 
mutations may have been introduced during storage. There are gaps in the collection 
which represent ‘black boxes’ of our investigation. The individual isolates represent 
single clones isolated from patient samples after growth on laboratory substrates and 
may or may not represent dominant subpopulations of the infecting bacteria; in all 
these cases the population diversity in the patient airways is unknown. Despite these 
and other problems we think that this CF strain collection is unique and sufficiently 
complete and representative for conclusive investigations of the evolutionary 
trajectories of some the bacterial cell lines which developed in the corresponding 
patients.  
We showed previously that at least two different genotypes (named b and r) were 
isolated from a large number of patients suggesting that transmission of bacteria had 
occurred among the CF patients in Copenhagen. One of these, the b clone, is the 
target of the present investigation. Based on a combination of PFGE and AT Chip 
analysis we found that out of 161 chronically infected patients who have been treated 
as one cohort, 42 had been infected with the b strain and many of them were carriers 
of the b strain over longer time periods. Among 40 isolates from 1973 (the oldest 
isolates in the collection) 4 were identified as b. Finally, a clone was isolated in 2007 
from a CF patient with a P. aeruginosa airway infection (first and last time for this 
patient) which turned out to be very closely related to the b clone. In a separate 
project we have monitored all colonizing clones of P. aeruginosa sampled from CF 
children and other patients with early infections in the Copenhagen CF Clinic during 
the last 5 years, and in no case except the one described above have we identified the 
b genotype. We therefore conclude that the b clone is present in the larger 
Copenhagen environment, but it does not seem to be a dominating genotype. The 
hypothesis that the b isolates in the clinic are descendants from a very early infection 
rather than new infections from the environment is supported by the observation that 
all b isolates except the 2007 strain described above share phenotypes with other 
chronically infecting strains (slow growth, antibiotic resistance, loss of, etc., see Table 
S1). In contrast to the well-adapted b isolates in older patients which cannot be cured, 
the b strain isolated from the newly colonized CF patient was successfully cured by 
antibiotic treatment and has not been seen since. 
In relation to the b clonal line of isolates we therefore assume that i) it has been 
present in CF patients of the Copenhagen CF Clinic since the early 1970s, ii) it has 
89 | P a g e  
 
been transmitted among many patients such that 20-25% of the chronically infected 
patients have been infected with the clone, and iii) a closely related clone with a very 
short recent infection history has been obtained. Due to the short period of 
colonization of the latter b like clone we consider it a putative wild-type 
environmental relative of the b adapted isolates in the CF patients. As such we have 
used it as a reference strain (referred to Wild-Type-b or wtb) for our detailed 
genotypic and phenotypic investigations. 
3.3.3 Evolutionary progression reflected by expression profiles  
To further characterize the adaptation of the b clone in the Copenhagen CF clinic, we 
first performed systematic comparison by DNA microarray analysis in 14 chosen 
isolates as well as PAO1. Figure 1 shows the clonal dynamics of P. aeruginosa isolates 
in the patients who we focused on. There were 4 isolates with the b genotype found in 
1973 isolated from 4 different patients. The b strains did not persist long in any of 
them, due to the fact that the patients died (CF42, CF112 and CF105) or strain 
substitution (CF66). In the case of CF66, after 1973 b isolates did not appear until 1992, 
but phenotypes of the isolates after 1992 bear more resemblance to other late isolates 
than to the one from 1973, indicating that the patient was re-infected with a b strain 
that was already adapted to the lung through transmission. Two isolates were used 
for expression profiling – CF43-1973 which is similar to environmental strains in 
phenotypes (Table S1) and CF66-1973 which is related to other later isolates in 
several gene sequences (Table S2 and following section). Patient CF30 carried the b 
genotype in 1979 once and was then dominated by the r clone afterwards. The CF30-
1979 isolate is the only one available for us between 1973 and 1984. Patient p7 is 
especially interesting because a very homogenous ‘b clone only’ pattern is found in 
the strain collection ever since 1991 when she was just diagnosed as chronic patient. 
Longitudinal samples from 1991, 1997, 2003, 2005 and 2007 were chosen for 
transcriptome analysis. Patients p6 and p10 also have a similar ‘b clone only’ pattern 
for a long time as p7, except they both experienced transition to r genotype in 2002 for 
p10 and 2005 for p6. Three isolates from 1984, 2002 and 2005 of p6 and a pair of r and 
b isolates from the same sputum sample of p10 in 2002 were chosen in the DNA 
microarray analysis. The strain wtb and PAO1 were used as environmental references. 
These isolates covered the whole period since b genotype was first found in the clinic 
in 1973 until year 2007 and contained diversity in terms of patients and genotypes.  
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Figure 1. Strain dynamics of focused patients. Blue box: b genotype; red box: r genotype; 
White box: other genotypes neither b nor r; Gray box: genotyping not performed; ‘m’ inside 
box indicates the mucoid phenotype (alginate production);     indicates dead patient. Bold 
box specify the strains that were used for transcriptome and metabolic profiling analysis. 
To obtain an overview of the microarray data, we performed principle component 
analysis (PCA) using singular value decomposition (SVD). The expression level of 
each gene is the mean values of 3 independent experiments (5 replicates in case of 
strain wtb). All the 5900 probes on Affymetrix Genechip PAO1 were used for 
calculation. PCA allows the visualization of data of 15 points in a space of 5900 
dimensions (a matrix of 15 strains and 5900 genes) in a two dimensional space. Figure 
2 shows the PCA plot in which the variance is projected on the first two principle 
components (SVDs) which captured the most variation between strains, 34% and 18% 
respectively. Surprisingly all the CF isolates harvested after 1979 form a large cluster, 
far way from environmental strains wtb and PAO1. The two isolates from 1973 were 
located in the between the above two big clusters. There are at least 3 important 
pieces of information that can be extracted from this figure. First, the cluster of late 
isolates contains strains from 4 different patients and 2 different genotypes, but they 
all behave with high level of homogeneity. This points towards that there are 
common evolutionary traits driven by the similar selective forces in CF lungs. Second, 
the late CF isolates are very distant from their environmental relative wtb, suggesting 
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that expression profiles of CF isolates have been deeply reshaped by genetic 
adaptation during the long term persistence. Third, projections of all the strains on 
the first SVD have a strikingly nice correlation with the isolation year. From right to 
left, we have environmental strains, 1973 isolates, 1979 isolate and later isolates, 
although the strains harvested after 1979 did not show strong time-dependent trend. 
 
Figure 2. Two-dimensional SVD plot showing the relationship between different isolates. 
Genotype was indicated by colours. Blue: b; Red; r; Green: PAO1. In the first two SVDs that 
capture highest percentages of variance (34% and 18%), all the strains fall into 3 major 
clusters: environmental representatives (PAO1 and wtb), intermittent isolates (1973 isolates) 
and all the late isolates. 
To further investigate this time-related correlation, we made a one-component 
analysis where the loadings of the first SVD are extracted and projected against the 
isolation years (Figure 3). We can see an unambiguous decline over time. The 
trajectory declined rapidly before 1979 and became flattened afterwards. Among the 
two 1973 isolates, CF42-1973 is more similar to wtb, while CF66-1973 is closer to the 
late isolates, which also agrees with the phenotypic data that CF66-1973 showed 
reduction in growth rate and motility. All the isolates after 1979 are relatively more 
similar to each other. However, if we zoom in to specific patient, we can still see a 
gradual progression. In p7 who has b clone persistence exclusively, 5 longitudinal 
isolates displayed a stepwise decreasing in their loadings in the first SVD, implying 
that most likely no strain transmission happened in the patient since 1991. In contrast 
to the consistency of p7 isolates, p6 strains showed a reduction in first SVD loadings 
from 1984 to 2002, but the trend reversed from 2002 to 2005, when strain transition 
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just occurred. This reflected a more complex pattern in the infection history of this 
patient, which could be the consequences of possible strain transmission, change of 
therapy, colonal diversity, etc. The isolate p10-2002 r (r genotype) also has similar first 
SVD loading with all the late b isolates although it has a different genome backbone, 
strongly suggesting the parallelism of evolution of P. aeruginosa infection in CF 
chronic patients. 
 
Figure 3. Time dependent progression of b isolates. Loadings of the first SVD were plotted 
against time. Error bars indicate standard deviations of the three replicates.  
To analyze the causes of this time-dependent progression, we extracted the top 2% 
genes that contribute the most to the first SVD, which are the genes that could best 
elucidate the change of transcriptional profiles over time, listed in Table S3.  
Interestingly, we can see many changes in gene expression levels correlating well 
with what we see in phenotype alterations. For example, there is decline in Quorum 
Sensing (QS), reduction in motility and increase in resistance to colistin from 
environmental isolates to early CF isolates and further to late CF isolates, and these 
can be explained in mRNA level by down-regulation of lasI, rhsI, flg/fli genes, and pilA, 
and up-regulation of arnB operon respectively. The next question is whether we can 
reveal the genetic alterations in regulatory genes that cause these expression changes. 
3.3.4 Evaluation of important mutations in mucA, lasR and rpoN. 
An apparent trend in Figure 2 and Figure 3 is that the expression profiles of the b 
clones changed dramatically from 1973 to 1979 but remained relatively stable after 
1979. One plausible explanation for this deceleration is that early mutations occurred 
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in global regulator genes which have essential benefits for the adaptation as well as 
numerous pleiotropic effects and thus have more influences in the transcriptional 
profiles. The later mutations involve only local alterations and small steps of 
adjustments, such as compensatory mutations to restore the deleterious side effects of 
previous mutations, or different switches in antibiotic resistance mechanisms in 
accordance to the change of therapies in patients. There are 3 candidate genes that 
have the properties of carrying both beneficial and pleiotropic effects, mucA, lasR and 
rpoN. The genes mucA and lasR had always been celebrities in CF study because they 
are frequently mutated in CF isolates. Elimination of mucA has potentially 
advantageous functions relating to the stress response (through derepression of AlgU) 
and virulence attenuation, besides induction of alginate (Rau et al., 2010, Garrett et al., 
1999, Wu et al., 2004, Govan & Deretic, 1996). Mutation of the gene lasR also plays 
important roles in turning down the virulence while also gaining certain metabolic 
functions (D'Argenio et al., 2007, Hoffman et al., 2009). RpoN which has been drawing 
less attention than the other two regulators in CF study, governs the transcription of 
large amount of genes responsible for virulence, motility, nitrogen and carbon 
metabolism. RpoN mutants were also reported to be isolated from CF patients and a 
defective rpoN gene was responsible for reduced swimming motility and resistance to 
nonopsonic phagocytosis in some of the isolates (Mahenthiralingam et al., 1994, Smith 
et al., 2006). 
By exploring the unfinished genome sequence drafts of 3 isolates p7-1991, p7-2007 
and wtb, we found all the 3 genes have mutations or deletions in p7-2007 and p7-1991 
isolates compared to wtb sequence. There is a single nucleotide deletion causing a 
frame shift in mucA gene, which most likely leads to loss of function of MucA protein. 
The fact that p7-1991 and p7-2007 strains are non-mucoid must be the consequence of 
reverting from a mucoid origin (mucA negative) at certain unknown sites. This 
reversion is not due to the change of K19→E in AlgU since it also exists in the b 
mucoid strains. Gene rpoN in this strain has a single nucleotide substitution causing 
an amino acid change L419→P, located in the DNA binding domain which is proximal 
to DNA in the promoter/holoenzyme complex. This mutation is also expected to have 
negative impact on RpoN function since it causes a change from non-polar amino 
acid to a polar one in such an important domain. The third gene lasR (PA4130) is 
completely missing because p7-2007 and p7-1991 strains have a ~5kb gap (referred to 
Del1) that totally removes gene PA1426- PA1431 and partially PA1425.  
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To characterize the impact of the rpoN mutation, we complemented rpoN with a 
wild type copy amplified from wtb strain using a low copy plasmid pMe6031. We 
tested the swimming motility and metabolism by Biolog Phenotype Chip. The result 
showed that complementation can restore 22-25% of the swimming motility 
measured by swimming zone in soft agar plates (Figure S2). Moreover, it also 
recovered various catabolic functions that RpoN regulates, especially utilization of 
alternative nitrogen sources, described in later text (Figure 4). All these results have 
suggested that L419→P mutation caused at least partial malfunction of RpoN in p7-
1991 and p7-2007 isolates.  
 
 
Figure 4. Dendrogram illustrating the relations of various strains based on Biolog 
Phenotype array data. Late b isolates (dark blue) and p10-2002 r (red) are distant from early 
b isolates (light blue) and PAO1 (green). When complemented with wild type copies of 
rpoN, p7_1991 and p7-2007 jumped to the same cluster with early b strains (p7_1991_rpoN 
and p7_2007_rpoN). P7_1991_p is the control where p7_1991 was only complemented with 
the empty plasmid. 
If these 3 mutations are overall beneficial, they should be kept in b population 
over time in the Copenhagen CF clinic. We then tracked back these 3 mutations in 
other isolates with a focus on the early ones. The mutations in mucA and rpoN were 
tested by sequencing and lasR deletion was examined by PCR (described in Materials 
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and Methods). All the 4 isolates from 1973 have mutations in mucA gene, but only 
strain CF66-1973 has the same one as the 29 later b isolates that we checked. CF66-
1973 also has the L419→P mutation identical to 7 later isolates. The lasR deletion Del1 
first occurred in CF30-1979 isolate and remained in all the later b strains (Table S2). 
Taken together, all 3 mutations in mucA, rpoN and lasR are fixed in the b population in 
over 40 patients through transmission. Mutations in mucA and rpoN already existed in 
CF66-1973 and this strain seems to be the clinical ancestor for all the b isolates. Del1 
deletion that removed lasR gene appeared in CF30-1979 for the first time. This isolate 
is also the first b strain that picked up all 3 important mutations, which correlates well 
with the observation that it already has very similar expression pattern with all the 
other late isolates but distinct from 1973 isolates. The stability of the 3 mutations in 
the b population points towards that they are favourable in the adaptation. 
To further evaluate the impact of the mutations in the 3 key regulators on the 
overall transcriptome changes of the late b isolates, we compared the expression data 
of CF30-1979 which carried the 3 mutations but very few other changes with the 
environmental representative wtb. We performed a student ttest and extracted the 
genes with p-value<0.01 and 786 genes were significantly different. We conducted 
similar analysis on a set of expression data of an intermittent CF isolate (mucA -) and 
its isogenic mucA+ pair from a previous study which was done under the same 
condition as ours (Rau et al., 2010). There were 1976 genes significantly changed due 
to the mucA mutation using the same statistical criteria. Between these two data sets, 
307 genes overlapped with the same trend in terms of up or down regulation. This 
means genes regulated by mucA mutation are highly represented in CF30-1979 isolate 
compared to wtb (Fisher’s exact test p-value = 1.1e-6). In previous investigations, gene 
sets regulated by RpoN and LasR were also determined. Due to the lack of raw data 
of these two data sets, we could only use the filtered gene lists which involved cut-off 
of certain fold change. Thus these two data sets might have underestimated the gene 
numbers regulated by the two genes, comparing to the analysis with no threshold of 
fold change. There were 62 genes regulated by RpoN (Dasgupta et al., 2003) and 35 
genes governed by LasR when cells were harvested at OD600 = 0.5 in LB medium 
(Schuster et al., 2003). There were 21 and 22 genes respectively overlapping with 786 
significant gene comparing CF30-1979 and wtb. Again, the genes regulated by rpoN 
and lasR are significantly represented in the CF30-1979 vs wtb comparison (Fisher’s 
exact test p-value = 0.02014 and 5.775e-5 respectively). Nineteen out of 21 genes that 
are controlled by RpoN are also in the list of mucA- vs mucA+ comparison. In total, 
among 786 significant genes comparing CF30-1979 against wtb, 331 genes are because 
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of the mutations in 3 genes mucA, rpoN and lasR, which is 42% of total number 
(Figure 5).  
We further assessed the effect of rpoN mutation on the metabolic profiles using biolog 
phenotype chip, since RpoN controls the metabolism of many carbon and nitrogen 
sources. We selected PM1, PM2 which are the carbon sources plates and PM3 which is 
the nitrogen plate for our assays. The area underneath the kinetic curves was used for 
analysis. Instead of focusing on changes of using specific substrates, we applied a 
hierarchical cluster analysis using data from all three plates (288 wells, 159 
informative), to have an overview of the effect of RpoN shown in Figure 4. Similarly 
with the expression data, separately from PAO1, all the late b clones (after 1979) are 
clustered together and separated from 1973 isolates and wtb. The separation of the 
two major clusters is because late isolates have reduced utilization of many substrates. 
However, p7-1991 and p7-2007 complemented with the wild type rpoN gene grouped 
together with the 1973 isolates. This figure has at least three implications. Foremost, it 
confirmed that the L419→P mutation is significant causing a reduction of the RpoN 
function. Additionally, relationships between different strains based on the metabolic 
profiles agreed with what was concluded from transcriptome data. More importantly, 
this strongly supports our hypothesis that the rpoN mutation has a significant impact 
on global changes in a variety of phenotypes and it is a huge step ahead in the 
adaptation process for P. aeruginosa. 
 
Figure 5. Visualization of impact of mucA, lasR and rpoN mutations on the overall 
transcriptional profiles of adapted b isolates. The numbers with underlines indicate the 
gene counts that overlap between the two comparisons. 
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In conclusion, both transcriptome and catabolic profiles have presented that the b 
clone experienced substantial evolutionary events from early 1970s to 1979 but 
remained more constant until 2007, despite that the strains have persisted for much 
longer time after 1979. Detailed analysis suggested that mutations 3 global regulators 
mucA, rpoN and lasR exerted essential control over this transition. 
3.3.5 Observation of parallel evolution  
So far we have described a dominant clone evolving in parallel in different patients 
generating a homogenous picture of the adapted P. aeruginosa clones. Most likely this 
is because the ancestor clone picked up important mutations very early which offered 
great advantage in the adaptation and enables the strain to spread easily in different 
patients. Thus it is not so called ‘parallel evolution’ by definition. Here we present an 
interesting observation which clearly showed b strains have developed the parallel 
traits independently during the evolution in individuals.  
In the genome of P7-2007 strain, we found a ~8 kb gap removing genes from 
PA4117 to PA4186 and partially PA4116 and PA4187, which is referred to Del2 in 
present study (Figure 6a). This region comprises one operon PA4120 –PA4128 
(referred to hpc operon) which is responsible for degradation of p-Hydroxy-
Phenylacetic Acid (4-HPA) (Zeng & Jin, 2003). 4-HPA is first converted to 
homoprotocatechuate (HPC) by products of hpaA and hpaC which are intact in p7-
2007 strain. HPC is degraded through a 7 step pathway by enzymes encoded by hpc 
operon into pyruvate and succinic semialdehyde (SSH), which eventually enters TCA 
cycle (Zeng & Jin, 2003) (Figure 6b). The lack of hpc operon leads to a deficiency of 4-
HPA catabolism, which is proved by the fact that p7-2007 strain could not grow in 
minimal medium using 4-HPA as a carbon source. We further checked if other strains 
carry this gap using a simple PCR (see materials and methods) and it turned out 
around 1/3 of all the b strains have the same deletion as in P7-2007, including earlier 
isolates from p7 (Table S2). This indicates Del2 deletion might have some selective 
advantage.  So we further examined the capability of more strains in utilization of 4-
HPA as carbon source. Surprisingly the capacity of degrading 4-HPA was largely 
reduced or lost in all the strains isolated after year 2000 and showed decline over time 
in patients p6, p10, CF89 and CF168 (Table S2), suggesting a strong selection against 
catabolism of 4-HPA. The first appearance of impaired growth on 4-HPA is in isolate 
CF30-1979, which is quite early in the evolutionary process of the b clone. 
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Figure 6. Parallel evolution of deficient hpc operon. a) The position of hpc operon in the 
genome and location of two gaps (Del2 and Del3) that lead to impaired hpc genes. b) The 
degradation pathway of 4-HPA and HPC. 
To uncover the genetic nature of reduced growth on 4-HPA in those b isolates 
which do not carry Del2, we designed 5 sets of primers covering most of the hpc 
operon to look for possible small deletions. A ~2kb gap (Del3) was identified in p6-
2002 and p6-2005 that causes full deletion of PA4121 as well as partial deletion of 
PA4122 and PA4120, which is the transcriptional regulator of the hpc operon (Figure 
6a) (Zeng & Jin, 2003). Del3 was also found in CF224-2002, but not in other isolates. 
When we performed PCR using different primers in this region, we noticed that other 
patterns of gaps apart from Del2 and Del3 might exist in some strains, but further 
characterization was not carried out.  For those with no apparent deletions such as 
CF-1979 and P6-1991, we sequenced PA4120 gene but no non-synonymous mutation 
was found. 
Here we did not attempt to identify all the causes of this phenotype in gene levels; 
what we can show is that the b genotype has developed the same trait – lost or 
reduced the ability catabolising 4-HPA, through distinct genetic paths, two of which 
were mapped out (Figure 6). This suggests that different lines must have evolved 
independently in individuals, which is a clear example of parallel evolution occurring 
in different patients. The evolutionary role of this trait is not known yet, but it must 
be beneficial for the b clone to persist in CF lungs since it was found repeatedly and 
separately.  
3.4 Discussion 
Experimental evolution with microorganisms allows us to observe evolutionary 
process in real time and understand natural selection in the genetic level. The genetic 
99 | P a g e  
 
basis underlining the evolutionary dynamics has been elucidated in simple defined 
conditions, but never been evaluated in a complicated and changing natural 
environment. Our study for the first time demonstrated the process of microbial 
evolution in a real-world situation – P. aeruginosa chronic infection in CF airways. 
Utilizing historical collection of P. aeruginosa CF isolates belonging to one 
dominant genotype b in the Copenhagen CF clinic, we estimated the evolutionary 
paths of P. aeruginosa adaptation in CF lung infection and determined some essential 
steps. An environmental b clone emerged in the CF clinic some time before 1973 and 
started to persist in CF airways through genetic adaptation. The b clone accumulated 
beneficial mutations in 3 global regulators by 1979, which significantly enhanced the 
adaptation and enabled it to transmit and dominate in many patients until now. This 
generated parallelism in the portraits of all late isolates in terms of transcriptome and 
metabolic profiles (Figure 7). The late isolates have been so severely remodelled 
during the evolution that they can not be identified as P. aeruginosa any more using 
standard phenotypic based diagnostic methods, indicating genetic adaptation has 
changed P. aeruginosa in the direction of creating a new ecotype which is a specialist 
thriving in CF airways.  
 
Figure 7. Model of development of important mutations and deletions of the b clone. 
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Dynamics of evolutionary adaptation revealed by several experimental evolution 
studies with bacteria and viruses have a common feature that fitness increase is rapid 
initially but decelerates over time (Cooper & Lenski, 2000, Novella et al., 1995). Due to 
the fact that there is no good model mimicking the human lung environment, we can 
not directly measure fitness of different P. aeruginosa isolates in CF airways or 
regenerate their evolutionary trajectory. However, global expression and metabolic 
profiles as well as other phenotypes (growth rate, motility, etc.) of sequential isolates 
exhibited a strong time dependent progression which could reflect the adaptation 
process: major changes happened before 1979 and the overall picture remained 
relatively stable in different patients afterwards for almost 30 years. This observation 
highly resembles the conclusion drawn from experimental evolution investigations 
where fitness can be directly quantified. 
Typically, early improvement of the fitness is achieved through few mutations 
with large benefits, rather than accumulations of many mutations with small benefits 
(Elena & Lenski, 2003). These are often in the regulatory genes with global impact on 
the expression of many genes. The b cell line successfully persisted probably owning 
to the early mutations in the 3 regulators mucA, lasR and rpoN. Mutation in mucA 
gene could activate the alternative sigma factor AlgU, leading to a hallmark 
phenotype of many CF isolates – mucoid colonies due to massive alginate production, 
which is believed to be profitable for P. aeruginosa to survive in CF lungs (Govan & 
Deretic, 1996). However more and more evidences implied the importance of 
pleiotropic effects of AlgT such as reduction of motility, QS and virulence in 
Caenorhabditis elegans model, as well as stress responses, and most of them are 
independent of alginate production (Rau et al., 2010, Wu et al., 2004). P. aeruginosa 
with lasR mutation and QS deficiency are often seen in CF isolates. LasR governs the 
QS signalling and also has global impact on the secreted virulence factors such as 
protease. RpoN is also an alternative sigma factor that regulates metabolism of many 
carbon and nitrogen sources as well as pili and flagella biosynthesis (Dasgupta et al., 
2003, Hobbs et al., 1993). RpoN knockout P. aeruginosa has dramatically decreased 
killing in various virulence models (Hendrickson et al., 2001). Apparently, all these 3 
regulators have functions in reduction of conventional ‘virulence’. In consistency with 
previous phenotypic characterizations, virulence factors that facilitate pathogens to 
invade or injure the hosts are very often eliminated during the chronic infection, as 
opposed to acute infections.  Immune evasion is a great advantage in chronic 
infection of CF patients probably due to better protection from host immune attacks 
as well as better preservation of host tissue for continuous nutrients supply.  
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The pleiotropic effects of rpoN mutation were further assessed using Biolog 
phenotype microarrays. In general all the chronic b strains isolated after 1979 have a 
decay of catabolic potential on almost all the substrates which separates them from 
those from 1973 and wtb (Figure S1). This decay is also the major reason of loss of 
identity on Biolog ID plates. Figure 4 clearly showed that this decline and parallelism 
of the decline is mainly because of the rpoN mutation. It is counterintuitive that P. 
aeruginosa actually have impaired catabolism on so many carbon and nitrogen sources 
in minimal medium conditions including amino acids which are very rich in the CF 
airways. One explanation is that decrease of motility and other virulence factors are 
the beneficial effects of rpoN mutation while decrease of catabolic functions are the 
evolutionary trade-offs. Cooper et al showed that populations evolved in glucose 
experienced reduction of catabolic functions of unused substrates and this occurred 
early and parallel in many independent lines (Cooper & Lenski, 2000). These 
observations suggested that this specialization is mainly contributed by antagonistic 
pleiotropy, which is the side effect of early mutations in global regulators. If the decay 
of catabolic functions that we see on Biolog phenotypic plates is due to the 
antagonistic pleiotropy of rpoN mutation, there are at least two possibilities for the 
causes. First, P. aeruginosa adaptation in CF lungs creates nutritional specialists and 
their preferred substrates are not included in the tests we performed. For example, 
there have been indications that fatty acids from airway surface liquid might be 
suitable carbon sources (Son et al., 2007), they are not present in Biolog Phenotype 
Plates. Second, it might also be relevant that nutrition utilization is not an important 
selective factor since the substrates availability is not constrained in CF airways. At 
least total amino acids can reach very high level in CF sputum samples (Palmer, 2009, 
Palmer et al., 2007). Even though those chronic isolates do not behave well in minimal 
media of different compounds, but in a rich media like CF sputa their growth is 
sufficiently active to support the regeneration and competition. Besides antagonistic 
pleiotropy, we can also not exclude the possibility that the reduction of catabolic 
functions is indeed beneficial itself. We have reported before that in the Copenhagen 
CF isolates many late chronic P. aeruginosa isolates with different genotypes have very 
similar growth rate in various media, which is 2-3 fold reduced compared to PAO1 
(Yang et al., 2008). The partially impaired metabolic profiles might provide an 
optimal growth rate which has proper biomass increase but does not induce too much 
immune response. Further understanding of this phenomenon requires detailed 
investigation of more P. aeruginosa population and nutrients availability in CF 
airways. 
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Parallel evolution typically appeared in a way that same genes were targeted 
through distinct changes in nucleotide level independently in different patients 
(Philippe et al., 2007). Parallel evolution is prevalent in nature and is strong evidence 
that similarities are derived from natural selection rather than random process. Apart 
from the consistency caused by the 3 pleiotropic mutations, we also described a case 
story of typical parallel evolution – deficiency of HPC pathway derived from two 
distinct deletions in the gene operon. Although the role of this phenotype in the 
evolution is not clear and still under investigation, appearance of parallel changes 
across multiple lineages strongly indicates that it is adaptive. We further tested 4 
randomly picked r strains isolated from 2002 to 2009 and 3 of them can grow well on 
4-HPA. Lacking of parallelism of r strains in this trait suggests impaired HPC 
pathway might be beneficial only in the b genotype and it is probably related to 
historical contingency of the b evolution. 
Besides the widespread of parallelism, we also observed diversity. For example, 
among the 4 isolates in 1973, there are 3 types of mucA sequences. But this diversity 
was eliminated later and only one type persisted because of the following beneficial 
mutations, which reflected a transient step of polymorphism during the selective 
sweep.  Another example is the heterogeneity of antibiotic resistance patterns of 
different strains, which is most likely the consequence of individual therapies 
received by the patients. Some of the causes have been investigated in p7 isolates. 
Mutations in pmrB and mexZ have been found in p7-1991 and p7-2007 compared to 
wtb, which might explain the resistance of these two strains towards colistin and 
tobramycin. In contrast to mutations in mucA, lasR and rpoN, these mutations have 
more ‘local’ impact on the expression network and respond to specific changes in the 
micro-environments, which is another level of genetic adaptation in the evolution. 
3.6 Conclusion and future directions 
The human airways are a heterogeneous and dynamic environment which is expected 
to generate diversities during P. aeruginosa evolution. However, the high levels of 
parallelism that we observed might reflect large extent of ecological homology in the 
lung environment, probably supported by coughing and treatments decreasing the 
mucus viscosity. It could also be because that the stresses from immune attack are 
very similar in different zones of the CF airways and thus eliminating the pathogenic 
display is the dominating trait evolved during P. aeruginosa adaptation. Nevertheless, 
the evolution of the b clones generated a consistent pattern in different patients 
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because early mutations that were highly adaptive made them successfully sweep 
across many patients and persisted. The end result of the evolution is a generalist 
capable of occupying all the niches in CF airway. However, we can not predict if this 
will be applicable to other P. aeruginosa infections in CF patients. The evolutionary 
dynamics of r genotype is right now under investigation to obtain a more completed 
picture of P. aeruginosa adaptation. Other driving forces other than random mutation, 
such as acquisition of novel genetic elements which could highly accelerate the 
evolution are also being studied by completion and careful inspection of the genome 
sequences. 
3.7 Materials and Methods 
3.7.1 Strains and growth conditions 
P. aeruginosa isolates were selected by plating sputum samples directly on 
Pseudomonas Isolation Agar (PIA) plates containing 100 µg/ml of ampicillin. Single 
colonies were cultivated and stored at -80°C with glycerol. The genotype of P. 
aeruginosa isolates was identified using either Pulsed Field Gel Electrophoresis (PFGE) 
or AT biochips (Clondiag Chip Technologies, Germany). All strains were cultured in 
Luria Broth (LB) at 37 °C unless otherwise noted. 
3.7.2 Sample preparation and array processing of DNA microarrays 
For transcriptome analysis, all P. aeruginosa strains were grown aerobically at 37 °C in 
LB medium starting from OD600 = 0.01 and harvested at OD600 = 0.5. Samples were 
prepared according to the prokaryotic sample and array processing protocol from 
Affymetrix (Santa Clara, CA). Harvested cells were mixed immediately with 
RNAprotect Bacteria Reagent (Qiagen) and stored at -80 °C. RNA was extracted with 
RNeasy mini kit (Qiagen) and transcribed to cDNA using SuperScript III Reverse 
Transcriptase (Invitrogen). The cDNA was purified with Qiagen PCR purification kit 
(Qiagen) and fragmented using DNase I (Promega). Fragmented cDNA was then 
labelled using labelling reagent (Affymetrix) and Terminal Deoxynucleotidyl 
Transferase (Promega). The labelled cDNA was hybridized on Affymetrix P. 
aeruginosa PAO1 gene chip and stained on GeneChip®  Fluidics Station 450. The probe 
arrays were finally scanned with GeneChip®  Scanner 3000. The raw data (.cel files) 
were obtained using the Affymetrix GeneChip®  Operating System 1.4 (GCOS). 
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3.7.3 Transcriptome data analysis 
Transcriptome data analysis was performed using BioConductor tools in R 
environment (www.bioconductor.org). Basic data processing including normalization 
and expression index calculation was done with RMA package (Bolstad et al., 2003). 
The principle component analysis was conducted with svd function. Pair-wise 
comparison by student t-test was performed using function t.test. 
3.7.4 Sequencing of lasR, mucA, algT and rpoN genes 
Sequencing of genes lasR, mucA, algT and rpoN was performed by PCR using High 
Fidelity DNA Polymerase (Fermentas) and four sets of primers: lasR fwd (5’- 
TCTCGGACTGCCGTACAAC -3’) and lasR rev (5’- AATTACCGATCGCCAGCTC –3’) 
for lasR gene, mucA fwd (5’- CTCTGCAGCCTTTGTTGCGAGAAG -3’) and mucA rev 
(5’- CTGCCAAGCAAAAGCAACAGGGAGG -3’) for mucA gene,  algT fwd (5’- CCTG 
AGCCCGATGCAATCCATTTTCG -3’) and  algT rev (5’-  GGACAGAGTTTCCTGCA 
GGGCTTCAC -3’) for algT gene, rpoN fwd (5’- CTCGCCAACGACCTGGTCAAG -3’) 
and rpoN rev (5’- GGCGTCGGTCACATCCAGTTG -3’) for rpoN gene. Another two 
primers were used for rpoN sequencing, rpoN seq1 (5’- GCCTGGGAAGACATCTA C 
CAGAC -3’) and rpoN seq2 (5’- GAGCTGAACCAGGAGGCGATG -3’).  
3.7.5 Verifying deletion regions 
The primers used for verifying the deletion region PA1425-1429 are del1fwd (5’- 
AAAGGAATCCAGCATGCACATTCG -3’) and del1rev (5’- AGCCTTTCTGTCCAG 
AGTTGATGG -3’). The strain carrying the deletion can produce a PCR fragment of 
732bp, while the wild type like strains will have a 5kb product. The primers to 
confirm the deletion region PA4116-4187 are del2fwd (5’- CCCAGGGCCTGAAGGA 
AGTG -3’) and del2rev (5’- CTGCTGCAGGTTCAGCGAAC -3’). PCR on strains with 
this deletion can give a band of 912bp and those do not have the deletion have no 
PCR products. To confirm that the latter one is not false negative, one gene in this 
region (PA4125) was amplified using primers set PA4125fwd (5’- GGCAGATCAAC 
GCGGTATT -3’) and PA4125rev (5’- GTTCAGGGTGCTGGCTGT -3’). The primers to 
verify the deletion region of PA4120-4122 are del3fwd (5’- GGTAGCCGGCAAGGTA 
GT -3’) and del3rev (5’-AGGGTCATGAAGCTGGAGAA-3’). These primers generate 
a 579bp DNA band those have this region deleted and a 2.5kb fragment was 
produced otherwise.  
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3.7.6 RpoN complementation 
A wild type copy of rpoN gene was amplified from wtb strain using primers rpoN 
NcoI fwd (5’- ATGCCATGGTGAAAACGGCGTATATCGTCA -3’) and rpoN EcoRI 
rev (5’- CCGGAATTCGTTGATGGCCACTGATGTTG -3’). The PCR fragment was 
digested with NcoI and EcoRI and ligated into pMe6031 vector (Heeb et al., 2000) 
creating plasmid pLYA. The plasmid pLYA was introduced into different strains by 
conjugation using the helper strain pRK600. Transformants were selected on PIA 
plates containing 60 µg/ml of tetracycline.   
3.7.7 Biolog Phenotype MicroarrayTM 
Phenotype MicroArrays (Biolog, Hayward, CA) was performed in duplicates 
according to the manufacturer’s instructions. P. aeruginosa strains were streaked on 
LB agar plates and incubated at 37 °C until colonies appeared on the plates (16-30 h). 
Cells were swabbed from the plates and suspended in IF-0 GN Base (inoculation fluid) 
at a density corresponding to 42 % transmittance in the Biolog turbidimeter. The cell 
suspensions were diluted 1:6 in IF-0 minimal medium containing Biolog redox dye 
mixture D (tetrazolium), and 100 μl aliquots were added to carbon source plates (PM1 
and PM2). For the nitrogen source plate (PM3), inoculations were supplemented with 
30 mM glucose and 2 μM of ferric citrate. The plates were incubated at 37 °C in an 
OmniLog plate reader, and growth/respiration was measured kinetically by 
determining the colorimetric reduction of tetrazolium dye. Of the total 285 substrates 
available on the three PM plates, 159 were found informative (supporting consistent 
growth between replicates for at least one strain and not autoinducing the color 
change). Export of OmniLog data was performed using OmniLog OL_FM/Kin 1.20.02 
software (Biolog). Average area underneath each kinetic curve is used for analysis. 
Hierarchical clustering analysis was performed in R with the package ‚squash‛ (A. C. 
Eklund).  
3.7.8 OmniLog Identification System  
OmniLog Identification System (Biolog) was used for test the identification of various 
strains. Assays were performed according to manufacture’s protocols except the 
incubation time was extended to 3 days due to the slow growth of certain strains. 
Identification was done in an automated manner by comparing the array pattern with 
Biolog Database. 3 strains were tested: wtb, p7-2007 (b) and p2-2005 (r). Strain wtb 
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was identified as P. aeruginosa, p7-2007 was only identified at genus level and p2-2005 
was not even identified at genus level. 
3.7.9 Phenotypic assays 
Motility: The twitching, swimming and swarming motilities were assayed on ABT 
plates (Lei’s paper ref 9) supplemented with 0.5% glucose and 0.5% casamino acid. 
1.5%, 0.3% and 0.6% of agar was used for twitching, swimming and swarming plates 
respectively. Bacterial cells were stabbed in the bottom, in the middle and on top of 
the plates for twitching, swimming and swarming motility, respectively. Twitching 
plates were incubated for 48 hours at 37 °C and the agar was removed to measure the 
twitching zone on the petri dishes. The swimming zones were measured after 24 
hours incubation at 30 °C, while the swarming zones were measured after 24-48 hours 
incubation at 37 °C. PAO1 knockout mutant ∆pilA (Klausen et al., 2003) was used as a 
negative control for twitching motility and ∆fliM (Klausen et al., 2003) was used as a 
negative control of swimming and swarming motility. 
Minimal Inhibitory Concentrations: Minimal Inhibitory Concentration (MIC) 
values of ciprofloxacin, tobramycin, aztreonam and colistin were measured using 
Etest®  strips (AB biodisk, Sweden) by plating 100µl of overnight culture on LB plates. 
The values were recorded after 48 h incubation in 37 °C.  
Quorum sensing:  Quorum sensing signal production were tested by streaking 
isolates and two E. coli monitor strains harbouring lasB-gfp or rhlA-gfp fusion 
(Hentzer et al., 2002) that can be induced by las signal molecule (3-O-C12-HSL) and rhl 
signal molecule (C4-HSL), respectively.  After 24 h of incubation at 37 °C, GFP 
production was visualized using a Zeiss Axion2 microscope with an integrated 
Coolsnap color cf camera at 2.5 Magnification and an exposure time of 200ms. Slow 
growing strains were incubated 8 hours before the monitor strains were applied to 
make sure that they are in stationary phase after 24 hours. 
Hypermutability:  Hypermutability was determined by mutation frequencies of 
rifampicin and streptomycin as described previously (Ciofu et al., 2008). The strain is 
considered to be hypermutable if it has 20 times higher mutation frequency than 
PAO1. 
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3.8 Supplementary materials 
Table S1 Phenotypes of selected strains 
CF 
No. 
DTU 
No. 
Isolation 
 Year 
Sample 
No. 
Doubling  
Time (min) 
las rhl Swimming Swarming Twitching CO TM CI AZ 
   PAO1 24 ++ ++ ++++ ++++ ++++ 7 2 0.19 1 
510 B54 2007 wtb 27 ++ ++ ++++ ++++ ++++ 6 2 1 3.5 
43  1973 206 34 ++ ++ ++++ ++++ ++++ 1.5 1 0.5 >256 
43  1984 19319A 41 ++ ++ ++++ - + 3 6 0.38 >256 
43  1985 20155 61 ++ ++ ++ - + 1.5 3 1 >256 
114  1973 218 26 ++ ++ ++++ ++++ ++++ 1 0.19 0.094 >256 
105  1973 208 33 - - ++++ - + 3 0.5 0.38 >256 
66  1973 217 50 ++ + + - - 3 1.5   0.75 64 
66  1992 20538 62 - - + - - 3 24 8 >256 
66  2008 5561A 56 - - + - - 6 24 12 >256 
66  2008 5561B * 90 - - + - - 0.38 16 24 >256 
30  1979 1912 51 - - + - - 1.75 4 0.32 >256 
173 p6 1984 18198 63 - - + - - 4 10 0.32 >256 
173 p6 2002 76863A 83 - - + - - 8 9 4 >256 
173 p6 2005 s1C2 72 - - + - - 7 5 5.5 >256 
333 p7 1991 14429 56 - - + - - 7 7 1 96 
333 p7 1997 15281 59 - - + - - >256 9 1 >256 
333 p7 2003 5896A 74 - - + - - >256 19 6 >256 
333 p7 2005 S1B1 76 - - + - - >256 24 4 >256 
333 p7 2007 0apr 78 - - + - - >256 26 3 >256 
333 p7 2007 apr * 109 - - + - - >256 21 2 >256 
243 p10 2002 75425E 110 - - - - - 1.75 16 >32 >256 
243 p10 2002 75425F r 61 - - - - - 1.75 16 >32 >256 
CO: colistin; TM: tobramycin; CI: ciprofloxacin; AZ: aztreonam. MIC values (µg/ml) were measured using E-test strips. Doubling times were 
measured in LB culture with shaking at 37°C. r: ‘r’ genotype, *: mucoid
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Table S2 characterization of strains and patients 
Patient 
No. 
Isolation 
Year 
sample 
No. 
mucA algT lasR rpoN 
PA4116-4187 
region 
Growth  
on  
4-HPA 
  PAO1 wt wt wt wt wt wt 
CF510 2007 wtb wt wt wt wt wt wt 
CF 43 1973 206 t352->c,118stop g349->t, 117stop wt wt n.d. wt 
CF 43 1984 19319A 
t352->c & g354->t,  
Q118->Y 
wt   
n.d. 
wt 
CF 43 1985 20155  wt   n.d. wt 
CF 114 1973 218 c382->t,128stop c448->g, R150->G wt wt n.d. wt 
CF 105 1973 208 t352->c,118stop c248->a, A83->E wt wt n.d. wt 
CF 66 1973 217 430∆g & frame shift 
g55->a, K19->E; 
116 insertion & frame 
shift 
g647->a, 
R224->G 
t1256->c, 
L419→P 
n.d. 
wt 
CF 66 1992 20538 430∆g & frame shift  Del1  Del2 No 
CF 66 2008 5561A 430∆g & frame shift  Del1  Del2 No 
CF 66 2008 5561B 430∆g & frame shift  Del1  Del2 No 
CF 30 1979 1912 430∆g & frame shift  Del1 t1256->c,L419→P n.d. p 
P2 1991 14495 430∆g & frame shift  Del1  Del2  
P2 1994 15286b 430∆g & frame shift  Del1  n.d.  
P2 2005 S1F6 r    wt 
t652->c,C218→R; 
g842->a,G281→D 
n.d. 
 
P7 1991 14429 430∆g & frame shift  Del1 t1256->c,L419→P Del2 No 
P7 1997 15281   Del1  Del2 No 
P7 2003 5896A   Del1  Del2 No 
P7 2004 34243   Del1  Del2 No 
P7 2005 S1B1 430∆g & frame shift g55->a, K19->E Del1  Del2 No 
P7 2007 Apr-00 430∆g & frame shift g55->a, K19->E Del1 t1256->c,L419→P Del2 No 
P7 2007 07apr-3* 430∆g & frame shift g55->a, K19->E Del1 t1256->c,L419→P Del2 No 
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P7 2007 07Nov* 430∆g & frame shift wt Del1  Del2 No 
p7 2008 07feb*  g55->a, K19->E Del1  Del2 No 
P6 1984 18198 430∆g & frame shift  Del1 t1256->c,L419→P n.d. wt 
P6 1991 11026 430∆g & frame shift  Del1  n.d. P 
P6 2002 76863A 430∆g & frame shift  Del1 t1256->c,L419→P Del3 No 
P6 2005 S1C2 430∆g & frame shift  Del1 t1256->c,L419→P Del3 No 
P10 1986 100 430∆g & frame shift  Del1  n.d. P 
P10 1991 15806 430∆g & frame shift  Del1  n.d. P 
P10 2002 75425E 430∆g& frame shift  Del1  n.d. P 
P10 2002 75425F r   
t530 ->c, 
L176 →P 
wt 
n.d. 
 
P11 2003 1299b 430∆g & frame shift  Del1  Del2 No 
P11 2005 S1F3 430∆g & frame shift  Del1  Del2 No 
P16 1985 48A 430∆g & frame shift  Del1  n.d.  
P16 1987 22125   Del1  n.d. P 
P16 1991 10318A 430∆g & frame shift  Del1  n.d. P 
P16 2002 7329B* 430∆g & frame shift g55->a, K19->E Del1  n.d. No 
CF 211 1991 15563 430∆g & frame shift  Del1  Del2 No 
CF 211 1997 50171a* 430∆g & frame shift  Del1  Del2 No 
CF 211 1997 50171b 430∆g & frame shift  Del1  Del2 No 
CF 211 2006 A11* 430∆g & frame shift  Del1  Del2 No 
CF 211 2006 F8/06 430∆g & frame shift  Del1  Del2 No 
CF 223 2002 2937C*   Del1  Del3 No 
CF 223 2002 2937B   Del1  Del3 No 
CF 131 2001 79740A   Del1  n.d. No 
CF 224 2002 2268A*   Del1  n.d. No 
CF 224 2002 2268C   Del1  n.d. No 
CF 222 2001 81819C   Del1  n.d. No 
CF 206 2002 3741A   Del1  Del2 No 
CF 206 2002 3741B*   Del1  Del2 No 
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CF 253 2002 2846C*   Del1  n.d. P 
CF 240 2002 13049B*   Del1  Del# P 
CF 240 2002 13049A   Del1  Del# P 
CF 180 2002 2943B   Del1  Del# No 
CF 180 2002 2943C*   Del1  Del# No 
CF 248 2002 44336   Del1  Del2 No 
CF 311 2002 14676B   Del1  n.d. No 
CF 311 2002 14676C   Del1  n.d. No 
CF 249 2002 51833   Del1  Del2 No 
CF 205 2002 2149B*   Del1  Del2 No 
CF 205 2002 2149A   Del1  Del2 No 
CF 178 2002 6286a   Del1  n.d. No 
CF 124 2001 77666B   Del1  Del2 No 
CF 231 2002 570A   Del1  n.d. No 
CF 126 2001 73236A*   Del1  n.d. No 
CF 126 2001 73236B   Del1  n.d. No 
CF 263 2001 79676B*   Del1  n.d. No 
CF 153 2001 82664B   Del1  n.d. No 
CF 153 2002 81461B   Del1  n.d. No 
CF 155 2001 74931A*   Del1  Del2 No 
CF 216 2002 6370A*   Del1  n.d. P 
CF 216 2002 6370B   Del1  Del2 No 
CF 273 2002 
8730/ 
8731 
  Del1  Del2 No 
CF 202 2002 9518B   Del1  n.d. No 
CF 229 2002 4945A*   Del1  n.d. No 
CF 229 2002 4945B   Del1  n.d. No 
CF 160 2002 4765   Del1  n.d. No 
CF 47 1991 14958   Del1  n.d. No 
CF 47 1995 11392A   Del1  Del2 No 
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CF 61 1984 19696   Del1  Del2 No 
CF 61 1999 68000D   Del1  Del2 No 
CF 21 1985 1738B   Del1  n.d. No 
CF 59 1991 14765B   Del1  n.d. No 
CF 59 1994 14724   Del1  n.d. No 
CF 89 1984 19234   Del1  n.d. wt 
CF 89 1995 6253A   Del1  n.d. No 
CF 168 1984 20688B   Del1  n.d. wt 
CF 168 1995 5284B   Del1  n.d. No 
1. Del: deletion; wt: wild type, identical or with silent mutations compared to PAO1; n.d.: not totally deleted, but not known whether the region is 
identical to wt; *, mucoid phenotype; r: ‘r’ genotype, besides the two strains marked ‘r’ and PAO1, all the other strains are b genotype; Blank: not 
checked 
2. Mutations are marked first with change in nucleotide level (small letters) and then with amino acid level (capital letters). Two different mutations in 
amino acid level in same gene are separated with ‘ ; ’. 
3. Highlighting colors: green, mutations are located in important domains; orange, mutations are not located in any known domains. 
4. Growth on 4-HPA was categorized into 3 types. No: no growth; wt: wild type growth; p: reduced growth 
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Table S3 Genes that contribute most to the first SVD 
ORF 
Gene 
Name 
Regulation # Product name 
PA0045  down hyperthetical protein 
PA0046  down hyperthetical protein 
PA0047  down hyperthetical protein 
PA0062  up hyperthetical protein 
PA0120  up probable transcriptional regulator 
PA0121  up hyperthetical protein 
PA0165  down hyperthetical protein 
PA0277  down conserved hyperthetical protein 
PA0291 oprE down 
Anaerobically-induced outer membrane porin OprE 
precursor 
PA0329  up conserved hyperthetical protein 
PA0365  up hyperthetical protein 
PA0366  up probable aldehyde dehydrogenase 
PA0588  up conserved hyperthetical protein 
PA0745  up probable enoyl-CoA hydratase/isomerase 
PA0762 algU up sigma factor algU 
PA0763 mucA up anti-sigma factor 
PA0807 ampDh3 up AmpDh3 
PA1077 flgB down flagellar basal-body rod protein FlgB 
PA1078 flgC down flagellar basal-body rod protein FlgC 
PA1079 flgD down flagellar basal-body rod modification protein FlgD 
PA1080 flgE down flagellar hook protein FlgE 
PA1082 flgG down flagellar basal-body rod protein FlgG 
PA1092 fliC down flagellin type B 
PA1093  down hypothetical protein 
PA1094 fliD down flagellar capping protein FliD 
PA1095  down hypothetical protein 
PA1096  down hypothetical protein 
PA1183 dctA up C4-dicarboxylate transport protein 
PA1228  down hyperthetical protein 
PA1323  up hyperthetical protein 
PA1324  up hyperthetical protein 
PA1431 rsaL down regulatory protein RsaL 
PA1432 lasI down autoinducer synthesis protein LasI 
PA1471  up hyperthetical protein 
PA1552  down probable cytochrome c 
PA1554  down probable cytochrome oxidase subunit (cbb3-type) 
PA1559  up hyperthetical protein 
PA1560  up hyperthetical protein 
PA1592  up hyperthetical protein 
PA1632 kdpF up KdpF protein 
PA1985 pqqA up pyrroloquinoline quinone biosynthesis protein A 
PA1999 dhcA up DhcA, dehydrocarnitine CoA transferase, subunit A 
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PA2014 liuB up methylcrotonyl-CoA carboxylase, beta-subunit 
PA2015 liuA up putative isovaleryl-CoA dehydrogenase 
PA2016 liuR up regulator of liu genes 
PA2018 mexY up 
Resistance-Nodulation-Cell Division (RND) multidrug 
efflux transporter 
PA2019 mexX up 
Resistance-Nodulation-Cell Division (RND) multidrug 
efflux membrane fusion protein precursor 
PA2247 bkdA1 up 2-oxoisovalerate dehydrogenase (alpha subunit) 
PA2248 bkdA2 up 2-oxoisovalerate dehydrogenase (beta subunit) 
PA2252  down probable AGCS sodium/alanine/glycine symporter 
PA2317  up probable oxidoreductase 
PA2381  up hyperthetical protein 
PA2445 gcvP2 down glycine cleavage system protein P2 
PA2446 gcvH2 down glycine cleavage system protein H2 
PA2485  up hyperthetical protein 
PA2562  up hyperthetical protein 
PA2634 aceA up isocitrate lyase AceA 
PA2779  up hyperthetical protein 
PA3031  up hyperthetical protein 
PA3038  up probable porin 
PA3049 rmf up ribosome modulation factor 
PA3147 wbpJ down probable glycosyl transferase WbpJ 
PA3148 wpbI down 
probable UDP-N-acetylglucosamine 2-epimerase 
WbpI 
PA3151 hisF2 down 
imidazoleglycerol-phosphate synthase, cyclase 
subunit 
PA3155 wbpE down probable aminotransferase WbpE 
PA3158 wbpB down probable oxidoreductase WpbB 
PA3159 wbpA down 
probable UDP-glucose/GDP-mannose dehydrogenase 
WbpA 
PA3179  down conserved hyperthetical protein 
PA3229  up hyperthetical protein 
PA3452 mqoA down malate:quinone oxidoreductase 
PA3552 arnB up conserved hypothetical protein 
PA3553 arnC up probable glycosyl transferase 
PA3554 arnA up conserved hypothetical protein 
PA3555 arnD up conserved hypothetical protein 
PA3556 arnT up inner membrane L-Ara4N transferase ArnT 
PA3557 arnE up conserved hypothetical protein 
PA3558 arnF up hypothetical protein 
PA3559  up probable nucleotide sugar dehydrogenase 
PA3602  up conserved hyperthetical protein 
PA3610 potD down polyamine transport protein PotD 
PA3691  up hyperthetical protein 
PA3692  up probable outer membrane protein precursor 
PA3722  down hyperthetical protein 
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PA3819  up conserved hyperthetical protein 
PA3904  down hyperthetical protein 
PA4070  up probable transcriptional regulator 
PA4073  up probable aldehyde dehydrogenase 
PA4101  up probable two-component response regulator 
PA4102  up probable two-component sensor 
PA4103  up hypothetical protein 
PA4104  up conserved hypothetical protein 
PA4105  up hypothetical protein 
PA4106  up conserved hypothetical protein 
PA4107  up hypothetical protein 
PA4110 ampC up beta-lactamase precursor 
PA4111  up hyperthetical protein 
PA4220  up hyperthetical protein 
PA4359  up conserved hyperthetical protein 
PA4525 pilA down type 4 fimbrial precursor PilA 
PA4607  up hyperthetical protein 
PA4645  down 
probable purine/pyrimidine phosphoribosyl 
transferase 
PA4773  up hyperthetical protein 
PA4774  up hyperthetical protein 
PA4775  up hyperthetical protein 
PA4776 pmrA up 
PmrA: two-component regulator system response 
regulator PmrA 
PA4777 pmrB up 
PmrB: two-component regulator system signal sensor 
kinase PmrB 
PA4781  up probable two-component response regulator 
PA4782  up hypothetical protein 
PA4880  up probable bacterioferritin 
PA5015 aceE down pyruvate dehydrogenase 
PA5016 aceF down dihydrolipoamide acetyltransferase 
PA5117 typA down regulatory protein TypA 
PA5178  up conserved hypothetical protein 
PA5182  up hyperthetical protein 
PA5192 pckA down phosphoenolpyruvate carboxykinase 
PA5212  up hyperthetical protein 
PA5298  down xanthine phosphoribosyltransferase 
# When the regulation is ‘down’,  the expression level of the gene decreases from right 
to left on the first SVD in Figure 2, and it is generally down regulated when infection 
progresses; vice versa. This table was co-contributed by Jens Vindahl Kringelum, 
Rasmus Lykke Marvig, Julie Serritslev , Mikael Holm Thomsen and Juliane Charlotte Thøgersen.
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Figure S1. Catabolic functions of b isolates. The catabolic function of each isolate is 
calculated as the average value of all the 159 wells relative to PAO1.  Isolates after 1979 have 
a significant decay compared to those from 1973. 
 
 
 
Figure S2. Swimming zones of A and B) p7-2007 complemented with wild type rpoN 
carrying vector; C) p7-2007; D) p7-2007 plus the vector without wild type rpoN. Diameters: A) 
16mm; B) 16mm; C) 13mm; D) 12mm. 
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Chapter 4 Conclusions, Discussions and Future 
Directions 
4.1 The longest microbial evolution ‘experiment’ creating a new 
ecotype 
P. aeruginosa persistence in chronic CF patients became the focus of our study not only 
due to its obvious clinical significance but also because it is an excellent model system 
to understand the microbial evolution in general and bacterial adaptation when 
switching from the environment to human lungs. 
 
 
 
 
 
 
 
 
Figure 1. Overview of strain dynamics in the LTEE setting (adapted from http://myxo.css. 
msu.edu/index.html) and the b clone development in Copenhagen CF centre (CPHCF). 
The unique ‘fossil’ collection of P. aeruginosa isolates from Copenhagen CF centre 
since 1973 allows us to perform the paleontological study of the b clone. Using FISH 
we could determine the in situ growth rates of P. aeruginosa in chronic CF lungs, 
which is around 115 min (doubling time) on average. This allows us to estimate the 
number of generations from 1973 to 2008. The b clone has adapted for about 150,000 
generations in a group of 42 patients since 1973, which makes it the longest microbial 
evolution ‘experiment’ ever reported (Figure 1). Moreover, this project is to study the 
120 | P a g e  
 
genetic changes from a long term adaptation in complex natural environments (CF 
lungs) instead of defined lab conditions, which is to our knowledge the first ever seen.  
If we make a portrait of the well adapted P. aeruginosa, we realize that evolution has 
shaped the bacterium so deeply that we could hardly recognize it is a P. aeruginosa. 
They have reduced growth rate in various lab conditions, decline in the production of 
classical virulence factors and decreased capacity of metabolizing different substrates. 
They even have no identities on Biolog Microbial Identification chips. Compared to 
environmental isolates, they are literally ‘losers’. However, inside CF airways they are 
able to out-compete environmental invaders. Thus, evolution has created a niche 
specialist of P. aeruginosa that can only thrive in CF lung environment where the 
stresses from immune attack and antibiotics are severe, with a trade-off of decreased 
fitness in other environments, such as simple lab media.  
In Lenski’s E.coli long term experiment, citrate was added in their experiment to 
inspect contamination because E. coli species can not grow on citrate. However, a 
novel variant that could utilize citrate derived from certain historical contingency 
during the evolution. They brought up the discussion whether this variant will 
eventually become distinct species (Blount et al., 2008).  One problem in bacterial 
systematics is that the definition of species is theory-free and only based on empirical 
criteria using molecular or genomic approaches (Cohan & Perry, 2007). Usually two 
members with in the species share over 70% homology in their genome content or 99% 
homology in 16sRNA. In our study, identities of the late b isolates were lost when 
they were tested based on metabolic profiles, but maintained in more conserved 
assays, such as FISH with probes targeting 16sRNA. Since mutation accumulation 
increases linearly over time (Barrick et al., 2009) (although late mutations might not 
give rise to profound phenotypic changes), we would expect given enough time they 
could eventually become two species distinct in genome content – one major in 
reproducing in natural environment and the other specializing to live in human CF 
airways. Most likely the evolution of b clone in CF patients is on the track of creating 
new species. So far the concept of ‘ecotype’ seems to be better describing the stage of 
the adapted b clones. Ecotype defines a group of bacteria that are ecologically similar 
to one another (Cohan & Perry, 2007). Long term genetic adaptation of P. aeruginosa in 
CF patients generated an ecotype that is dedicated to survival in CF airways and 
ecologically distant from their environmental relatives. 
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4.2 Evolutionary paths: Genetic adaptation and more 
Despite the fact that we could not directly measure fitness of various P. aeruginosa 
isolates in CF airway, we can still obtain an approximation of the evolutionary 
dynamics of the b clone adaptation based on transcriptional and metabolic changes. 
Most likely fitness gain was profound by 1979 and much slower afterwards until now. 
The early fast fitness increase was mainly due to mutations in 3 regulatory genes lasR, 
mucA and rpoN. They are adaptive most likely through down-regulation of various 
virulence factors. The also have side effects due to their global regulatory networks. 
For example mutation in rpoN led to impaired metabolic profiles. It would be 
interesting to find out if there are compensatory mutations that could restore some 
pleiotropic effects of previous adaptive mutations, which give rise to small benefits.  
Besides the b clone, there is another dominant clone belonging to the r genotype. 
It would be appealing to investigate if it follows the same dynamic as the b clone, and 
if the same beneficial pleiotropic mutations occurred early as well. There are also 
strains that are able to persist in one patient but inadequate to transmit, which are 
also interesting to study. All these investigations will give us a more complete picture 
of evolution dynamics of P. aeruginosa adaptation in CF patients. 
Our study has described how a P. aeruginosa clone went through genetic changes 
(mutations and deletions) from an environmental strain to a strain fully adapted to 
the lung, which is very much comparable to isolated pure culture evolving in a 
constant condition. However, different microbes in patient airways are not isolated 
from each other and there could be horizontal gene transfer among bacteria. Various 
genes associated to virulence or antibiotics resistance can be carried by mobile genetic 
elements (plasmids, phages, transposons and integrons) or variable regions of the 
chromosome (e.g. pathogenicity islands). They are horizontally transferred by means 
of transformation, conjugation or transduction. Gene gaining by horizontal gene 
transfer could dramatically speed up the evolutionary process. These traits belonging 
to so called ‘evolution by acquisition’ have not been inspected in the present study. 
The CF lung environment is a dynamic and complex system which should favour 
diversity. So far we have described a homogenous picture of b clone evolution due to 
the 3 highly adaptive mutations it ‘luckily’ picked up very early. But in certain 
functions or conditions, there could be diversities formed for various reasons, such as 
spatial heterogeneity due to the difference in micro-environments in the lung, 
diversity maintained by cooperation and cheating, phenotypic variation determined 
by fluctuating environments, polymorphism caused by high mutation rates, etc. The 
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next phase of our studies will have a focus on the diversity occurring during the 
adaptation and compared it with the dynamic of the b clone. 
Considering that CF lung is like an open ‘playground’ with many species to co-
exist, the interaction and parallel evolution of different microorganisms is an 
attractive to study. These might have affected the evolutionary dynamics of each 
individual species.   
Besides, the differences among individuals in terms of immune responses or 
airway conditions could lead to distinct evolutionary progresses of P. aeruginosa. 
However, this subject itself is extremely complicated and so far we can only assume 
all patients are more or less the same. The change from environment to human body 
is much larger and dominant in driving the evolution. 
In conclusion, P. aeruginosa adaptation in CF patients could be a consequence of 
different elements combined and some of them are more important than others. The 
efforts that we make to understand the bacteria adaptation mechanism will 
eventually help us discover new solutions to prevent or cure persistent infections. 
4.3 Parasitic symbiosis: Is pathogenesis an evolutionary ‘mistake’? 
Although in this thesis we focused attention on interpreting the evolutionary process 
of P. aeruginosa adaptation to the CF airways, eventually we hope to obtain better 
understanding of pathogenesis of P. aeruginosa infection and find improved 
therapeutic solution for CF patients. We have presented a model describing P. 
aeruginosa evolution in chronic CF patients through mutations. Early mutations in 
three important genes lasR, mucA and rpoN all play roles in reduction of classical 
virulent factors (Figure 2), suggesting that the traditional view of virulence is not 
applicable in chronic infection of P. aeruginosa in CF patients.  We have mentioned in 
section 1.1.1 that P. aeruginosa can cause both acute infections like bacteraemia killing 
the host in days and chronic infection that can last for decades. What makes them to 
decide whether to damage the host using virulent factors or to drop their ‘weapons’ 
and have a steady life in the host? How should we define virulence in such chronic 
infection? 
To answer this question, we need look beyond Pseudomonas and learn from other 
symbiosis relationships. Mycobacterium tuberculosis for instance, the predominant 
cause of airway infection tuberculosis can persist in human airways by maintaining a 
dormant form (also see 1.3.4) and patients do not exhibit clinical evidence of active 
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disease. M. tuberculosis in this form is non-culturable and insusceptible to drugs.  
However, when the immune system is suppressed (e.g., co-infection with HIV), M. 
tuberculosis can escape immune surveillance and establish overt disease. But it is very 
common that after chemotherapy M. tuberculosis relapses into the quiescent state and 
persists (Trucksis, 2000). The M. tuberculosis persistence is a parasitic symbiosis in a 
fine-tuned fashion that has evolved over time between the bacterium and host. 
Evasion of immune responses by reducing antigenic presentation during persistence 
has also been observed in Salmonella enteria serovar Typhi and H. pylori long-term 
inhabitation in individuals who do not develop overt diseases (Monack et al., 2004). 
Similarly, P. aeruginosa is also trying to be invisible for host immune response, by 
attenuating toxin production through gradual genome alterations but keeping 
relatively high growth rate. 
What is the role of ‘virulence factors’ for bacteria in the context of co-evolution 
between microbes and their eukaryotic neighbours for millions of years? If we 
compare parasitic symbiosis with mutualistic (beneficial) symbiosis, we can see a 
striking homology in the apparatuses that microbes use to ‘damage’ or ‘help’ the host.  
For example, in the beneficial association between Vibro fischeri and monocentrid 
fishes, V. fischeri uses QS to control transcription in high cell densities, whereas QS 
has been considered as one of the major toxins in P. aeruginosa. A type III secretion 
system was found to be critical to transfer of the bacterial cells into the host 
bacteriocytes in a mutualistic symbiosis between grain weevils and their bacterial 
endosymbionts (Dale et al., 2002), while type III secretion system is recognized as a 
key virulence factor in many bacterial pathogens. McFall-Ngai and Gordon presented 
a view about this convergence of the beneficial and pathogenic interactions. If 
symbiotic evolution is driven by selection of organisms that can thrive through the 
interaction of their counterparts, beneficial symbiosis should be the rule rather than 
the exception, while pathogens may have perverted their relationships with their 
hosts (McFall-Ngai & Gordon, 2006). In this sense, it is counterproductive for 
pathogens to destroy their hosts, which are their sources of nutrition. Pathogenesis 
might be an evolutionary ‘mistake’ in which the microbe-host alliance fall apart 
(Kolter & Hogan, 2006). 
If we come back to the story of P. aeruginosa, how can we interpret the long-term 
association between P. aeruginosa and human? Can we consider the adaptation of P. 
aeruginosa through loss of virulence as actions to correct this ‘mistake’? The fact that P. 
aeruginosa can persist better than other pathogens in CF lungs might not be because 
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they are better to invade, but they are better to compromise. P. aeruginosa is rather a 
‘victim’ than a ‘winner’ in the interaction with their host – CF patients. Being silent 
might the best way to survive in a host then beneficial symbiosis can not be 
established. Compared to bacteraemia that can destroy the host very fast, chronic 
infection is better for reproductive success in the long run because it preserves their 
colonizing niches. The driving force of establish chronic or acute infection is to large 
extend on the side of the host, including how strong immune response is and how 
efficient the chemotherapies are. 
Based on limited data available, we could speculate the following model giving a 
novel view of pathogenesis: microbial infection happens when the microorganism 
enters a ‘wrong’ host where beneficial association can not be established. In case of 
acute infection, pathogens are either cleared out quickly by antibiotics or immune 
defence or causing mortality of the host. Either way, there are no steady relationship 
between pathogens and the host. In case of chronic infection, the host suppression 
(including both immune defences and antibiotic treatment) is probably moderate, 
neither too strong to eradicate the bugs, nor too weak to be overwhelmed by the 
microbial proliferation. Thus pathogens have time and are selected to adjust their 
dialogs with the host, by switching growth mode or genetic adaptation or other 
mechanisms, and a relative long-term equilibrium can be sustained between the two.  
Finally, it is essential to know that P. aeruginosa infection in CF patients are 
constantly active, and there is no latent phase when patients experience no symptoms 
at all as in M. tuberculosis persistence. Besides passively removing the antigenic 
molecules, P. aeruginosa have properties that help the bacteria actively defend 
themselves against the host attack and explore nutrients or important substrates, 
which we suggest should be referred to the real ‘virulence factors’ for such kind of 
chronic infection, including antibiotic resistance, stress response triggered by AlgT 
activation, and other traits yet to be identified. 
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